UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, ~~2025~~2026

☐

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-11737

NORDICUS PARTNERS CORPORATION

(Name of ~~small~~registrant ~~business~~as ~~issuer~~specified in its charter)

Delaware

04-3186647

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

280 South Beverly Dr., Suite 505, Beverly Hills, CA		90212
(Address of principal executive offices)		(Zip Code)

Issuer’s telephone number (310) 666-0750

Securities registered under Section 12(b) of the Exchange Act:

None		None
Title of each class		Name of each exchange on which registered

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	☐ Large Accelerated Filer	☐ Accelerated Filer
	☒ Non-accelerated Filer	☒ Smaller reporting company
	☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

~~Indicate by~~The ~~check~~aggregate ~~mark~~market ~~whether~~value of the registrant’s iscommon astock, ~~shell~~par value ~~company~~$0.001 ~~(as~~per ~~defined~~share, inheld ~~Rule~~by ~~12b~~non-2affiliates of the ~~Act).~~registrant, ~~Yes~~as ☐computed Noby ☒reference to the September 30, 2025 closing price reported by OTCQB, was approximately $21,126,694.

~~State~~As ~~the aggregate market value~~ of ~~the~~July ~~voting~~14, ~~and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold~~2026, orthere ~~the~~were ~~average bid and asked price of such common equity~~19,173,896 asshares of the ~~last business day of the~~ registrant’s ~~most~~ ~~recently~~Common ~~completed~~Stock ~~second fiscal quarter~~outstanding. ~~$5,466,882 as of September 30, 2024.~~

AsNORDICUS ofPARTNERS ~~July~~CORPORATION ~~16,~~AND ~~2025, there were 17,487,138 shares of the registrant’s Common Stock outstanding.~~SUBSIDIARIES

~~NORDICUS~~TABLE ~~PARTNERS~~OF ~~CORPORATION~~CONTENTS

FORM 10-K

		Page
PART I
Item 1.	Business	3
Item 1A.	Risk Factors	6
Item 1B.	Unresolved Staff Comments	6
Item 1C.	Cybersecurity	7
Item 2.	Properties	7
Item 3.	Legal Proceedings	7
Item 4.	Mine Safety Disclosures	7
PART II
Item 5.	Market Information for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6.	[Reserved]	11
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.	16
Item 8.	Financial Statements and Supplementary Data	17
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	18
Item 9A.	Controls and Procedures	18
Item 9B.	Other Information	18
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	19
Item 11.	Executive Compensation	21
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	24
Item 13.	Certain Relationships and Related Transactions, and Director Independence	26
Item 14.	Principal Accounting Fees and Services	27
PART IV
Item 15.	Exhibits, Financial Statement Schedules	28
Item 16.	Form 10-K Summary	29
	Signatures	30

FOR THE YEAR ENDED MARCH 31, 2025

INDEX

		Page
PART I
Item 1.	Business	3
Item 1A.	Risk Factors	6
Item 1B.	Unresolved Staff Comments	6
Item 1C.	Cybersecurity	6
Item 2.	Properties	6
Item 3.	Legal Proceedings	6
Item 4.	Mine Safety Disclosures	6
PART II
Item 5.	Market Information for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6.	[Reserved]	10
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.	16
Item 8.	Financial Statements and Supplementary Data	17
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	18
Item 9A.	Controls and Procedures	18
Item 9B.	Other Information	18
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	19
Item 11.	Executive Compensation	21
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	23
Item 13.	Certain Relationships and Related Transactions, and Director Independence	25
Item 14.	Principal Accounting Fees and Services	26
PART IV
Item 15.	Exhibits, Financial Statement Schedules	27
Item 16.	Form 10-K Summary	27
	Signatures	28

Part I

Item 1. Business

Corporate History

We were founded in 1993, ~~and~~reincorporated in ~~2007 were reincorporated from a Massachusetts corporation to a~~ Delaware ~~corporation.~~in We2007, changed our name ~~from~~ ~~CardioTech International, Inc.~~ to AdvanSource Biomaterials Corporation, ~~effective~~in ~~October 15,~~ 2008. Onand ~~March 3, 2020, we~~ changed our name to EKIMAS Corporation in 2020.

On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company (“Reddington”) providing for ~~the~~Reddington’s purchase of a total of 511,448 shares of our common stock, on a post-split basis, or approximately 90% of our total ~~shares~~outstanding of common stock, ~~outstanding~~ for total cash consideration of $400,000. Reddington ~~purchased~~ purchased the common stock in two tranches, which closed on October 12, 2021 (the “First Closing”) and March 15, 2022.

Pursuant to the SPA, the Company ~~effectuated~~effected a 1-for 50 reverse stock split on March 11, 2022 (the “Reverse Split”). ~~Accordingly, on~~On a post-split basis, ~~the~~Reddington ~~shares~~acquired ~~purchased~~42,273 inshares ~~connection~~at ~~with~~ the First Closing ~~resulted~~and inan ~~Reddington~~additional ~~owning 42~~469,~~273~~175 shares ofat ~~our common stock. As set forth in~~ the ~~SPA, Reddington then purchased from us on~~ March 15, 2022, ansecond ~~additional 469~~closing,~~175~~ after ~~shares~~which of our common stock, on a post-split basis (the “Second Closing”). After the issuance thereof Reddington owned 511,448 shares of our common stock, or approximately 90% of our total ~~shares~~outstanding of common stock ~~outstanding~~.

On February 23, 2023, the Company ~~and~~acquired NP Bioinnovation A/S (formerly Nordicus Partners A/S and Managementselskabet af 12.08.2020 A/S), a a Danish stock corporation, ~~consummated~~pursuant ~~the~~to ~~transactions contemplated by~~ a ~~certain~~ contribution agreement ~~(the~~with ~~“Contribution Agreement”) by and among the Company,~~ NP Bioinnovation A/S, GK Partners ApS ~~(“GK Partners”)~~, Henrik Rouf and Life Science Power House ~~ApS~~ ~~(“LSPH”) (GK Partners, Rouf and LSPH are collectively referred to herein as the “Sellers”, and each individually as a “Seller”)~~ApS. ~~Pursuant~~The tosellers ~~the Contribution Agreement the Sellers~~ contributed, ~~transferred, assigned and conveyed to the Company all right, title and interest in and to one hundred percent (~~100%) of the issued and outstanding capital stock of NP Bioinnovation A/S to the Company in exchange for an aggregate of 250,000 shares of the Company’s ~~Common~~common ~~Stock~~stock, ~~par~~and ~~value $0.001 per share. As a result of this transaction,~~ NP Bioinnovation A/S became a ~~100%~~ wholly owned subsidiary of the Company.

On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company.

On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD.

On June 1, 2023, the Company acquired a 4.99% interest in Mag Mile Capital, Inc., a ~~full-service~~ commercial real estate mortgage banking firm headquartered in Chicago ~~with offices in the states of New York, Massachusetts, Connecticut, Florida, Texas and Nevada~~. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the full capital stack and across all major real estate asset classes nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneurs.

On June 9, 2023, Mr. Tom Glaesner Larsen resigned as a director of the Company and Henrik Keller was appointed as his replacement.

On November 29, 2023, the Company’s subsidiary, Nordicus Partners A/S, changed its name to Managementselskabet af 12.08.2020 A/S. Subsequently on March 10, 2025, Managementselskabet af 12.08.2020 A/S changed its name to NP Bioinnovation A/S.

On May 13, 2024, the Company acquired a 95% interest in Orocidin A/S (“Orocidin”), a Danish preclinical-stage biotechnology company advancing next-generation of periodontitis therapies, in exchange for 3,800,000 restricted shares of the Company’s common stock.

On May 13, 2024, the Company and certain shareholders of Orocidin A/S (the “Orocidin Sellers”), a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Orocidin Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock. In exchange, the Company issued 3,800,000 restricted shares of its common stock to the Orocidin Sellers. The transaction was consummated on May 13, 2024. Orocidin A/S, is a preclinical-stage biotechnology company which is advancing the next generation of periodontitis therapies.

On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement.

On November 8, 2024, the Company ~~effectuated~~effected a 1-for-10 reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares. The ~~Reverse~~reverse ~~Stock~~stock ~~Split~~split had no effect on the Company’s authorized shares of common stock or preferred stock and the par value ~~will~~of ~~remain~~each ~~unchanged~~class atremained $0.001~~, respectively~~. All common stock share, option, warrant and per share amounts (, except our authorized but unissued shares), have been retroactively adjusted in these consolidated financial statements and related disclosures.

On November 11, 2024, the Company announced that it entered into an agreement with Bio-Convert A/S (“Bio-Convert”) to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 restricted shares of the Company’s common stock. Bio-Convert is a Denmark-based preclinical-stage biotechnology company aiming to revolutionize the treatment of oral leukoplakia by minimizing or removing oral leukoplakia lesions in order to further reduce the risk of such lesions resulting in the development of oral cancer in patients.3

On November 1211, 2024, the Company announced that it had entered into an agreement ~~with Orocidin A/S~~ to acquire ~~the~~100% ~~remaining~~of ~~29,663~~the outstanding shares, ~~or approximately 5%,~~ of ~~Orocidin~~ Bio-Convert A/S. ~~In exchange~~(“Bio-Convert”), ~~the~~a ~~Company~~Denmark-based ~~issued~~preclinical-stage ~~200,000~~biotechnology ~~shares~~company ofdeveloping ~~restricted~~treatments ~~common~~for ~~stock~~oral ~~to the selling shareholders of Orocidin.~~leukoplakia, ~~Upon~~in ~~closing~~exchange offor ~~the acquisition~~12,000,000 ~~Orocidin~~restricted ~~A/S~~shares ~~became a 100% wholly owned subsidiary~~ of the Company’s common stock.

On November 12, 2024, the Company acquired the remaining 29,663 outstanding shares, or approximately 5%, of Orocidin A/S, in exchange for 200,000 restricted shares of of the Company’s common stock, after which Orocidin A/S became a wholly owned subsidiary of the Company.

On August 7, 2025, (1) Henrik Keller resigned from the Board of Directors of the Company, (2) the Board increased its size from three to five members and (3) Torben S. Jensen, Kim T. Mücke and Andrew J. Ritter were appointed to fill the resulting vacancies. The Company executed a director agreement with each of Messrs. Jensen, Mücke and Ritter, under which each will receive an annual cash retainer of $10,000, payable in two installments per calendar year in accordance with the Company’s standard compensation plan for Board members. Messrs. Jensen and Mücke also each received options to purchase 25,000 shares of the Company’s common stock at $1.90 per share, and Mr. Ritter received options to purchase 50,000 shares of the Company’s common stock at $1.90 per share. All such options were fully vested on the date of grant and issued as incentive stock options under, and subject to the terms and conditions of, the Company’s 2024 Stock Incentive Plan.

In October 2025, the Company formed NoviThera ApS (“NoviThera”) to research and develop monoclonal antibody (MaB) therapy for the treatment of psoriasis. The invention and initial development were made and performed by Alteral Therapeutics (“Alteral”), a Denmark-domiciled related party of the Company. Mr. Allan Wehnert, who controls Alteral, was appointed Chief Executive Officer of NoviThera. In exchange for contributing intellectual property to NoviThera, Alteral received a 49.9% ownership interest in NoviThera, and the Company retained a 50.1% ownership interest.

On November 10, 2025, the Board created (1) a Nominating and Corporate Governance Committee, consisting of Peter Severin (Chairman), Kim T. Mücke and Andrew J. Ritter; (2) an Audit Committee, consisting of Kim T. Mücke (Chairman), Peter Severin and Andrew J. Ritter; and (3) a Compensation Committee, consisting of Andrew J. Ritter (Chairman), Peter Severin and Kim T. Mücke. The Board also adopted a Code of Conduct and Ethics, an Insider Trading Policy, a Whistleblower Policy and a Compensation Recovery Policy.

Our Business

~~Since the current leadership assumed control of~~ Nordicus Partners Corporation (“Nordicus” or the “Company”), ~~the~~U.S. ~~Company~~publicly listed biotech company specializing in developing ~~has~~breakthrough ~~evolved~~therapeutics ~~into~~in adiseases ~~leading~~with Uunmet medical needs.S. ~~publicly~~Nordicus ~~listed~~focuses ~~business~~on ~~accelerator~~acquiring and ~~holding~~developing ~~company~~drugs ~~dedicated~~from toinnovative ~~helping~~biotech companies ~~Nordic~~in the Nordics, a region known for its brilliant scientists, exceptional life ~~sciences~~science ~~companies~~ecosystem and drug discoveries ~~succeed~~and developments. Nordicus is dedicated to developing breakthrough therapeutics in ~~the~~diseases ~~American~~with ~~market~~unmet medical needs – starting with oral disorders. ByIts ~~combining~~scientific ~~Nordic~~foundation ~~innovation~~targets ~~with~~inflammation Uand immune modulation.S. ~~operational~~In ~~expertise~~2024, Nordicus ~~Partners~~acquired ~~Corporation~~100% ~~creates~~of Orocidin A/S, a ~~distinct~~Danish ~~advantage~~preclinical-stage inbiotech ~~identifying,~~company ~~scaling,~~developing next-generation therapies for periodontitis and ~~exiting~~100% ~~high~~of Bio-~~potential~~Convert ~~companies~~A/S, ina Danish ~~fast~~preclinical-~~growing~~stage ~~markets~~biotech ~~with~~company ~~unmet~~dedicated ~~medical~~to ~~needs~~revolutionizing the treatment of oral leukoplakia.

Nordicus’ ~~mission~~portfolio isdiversification tostrategy ~~back~~positions ~~high-growth~~it ~~ventures~~as ~~and~~a ~~transformative~~stable ~~innovations in the life sciences sector. By providing capital, strategic guidance,~~ and ~~operational~~resilient ~~resources~~company, wemitigating ~~unlock~~risk ~~each~~with ~~company’s potential to generate~~ significant ~~value~~upside ~~and drive robust financial returns~~potential. ~~Our hands-on approach—engaging, empowering, and capitalizing our portfolio companies—actively propels their success.~~

Our approach blends strategic counsel, operational know-how, and the cultivation of meaningful partnerships. This integrated support strengthens our companies’ market positions and helps them achieve their growth ambitions. Drawing on the combined expertise of our skilled Nordic and U.S. teams, we deliver a unique perspective that advances each portfolio company toward its full potential.

Nordicus’ portfolio diversification strategy positions us as a stable and resilient company, mitigating risk with significant upside potential.

Our Approach and Value Creation Process

Nordicus employs a 4-step value creation process:

	–	Scout and Accelerate: Nordicus targets high-impact potential companies, providing capital, resources and expertise to drive critical milestones such as patent filings and clinical trials.

	–	Acquire and Exit: Nordicus acquires controlling stakes to maximize value creation and exit at premium multiples.

We scout the Nordic region looking for early-stage life sciences companies developing drugs or treatments for diseases in high growth markets with significant unmet medical needs, all in potential multibillion USD markets.

After a vigorous due diligence process, the chosen companies will be offered to join Nordicus’ accelerator program. Once the chosen companies have become accelerator clients, Nordicus takes an active role in advising the management team, assisting with strengthening the companies’ Board of Directors and establishing Advisory Boards including making introductions to strategic partners and talent.

Once the milestones – set by Nordicus – are met, Nordicus will typically offer to acquire the companies outright. The first three acquisitions will be all-stock transactions, with the first two acquisitions (Orocidin A/S and Bio-Convert A/S) having already been completed, fitting Nordicus’ criteria of inclusion.

Nordicus aims to take all portfolio companies’ drug developments through Phase I. Upon completion of Phase I, the following options will be considered:

	1.	Sale or merger of the portfolio company.

	2.	Further development through the next clinical phases.

	3.	Strategic partnership with a large pharmaceutical company that will invest in Nordicus for further drug development.

	4.	Stand-alone Initial Public Offering (IPO).

Nordicus’ current life sciences portfolio consists of two promising preclinical biotechnology companies in Orocidin A/S and Bio-Convert A/S ~~led~~ led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of both companies. In October 2025 Nordicus formed a third subsidiary, NoviThera, also to be led by Allan Wehnert.

Orocidin A/S is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis, with Bio-Convert A/S focused on a treatment against oral leukoplakia (OLK) – an oral potentially malignant disorder – by developing a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.

The companies’ innovative breakthroughs are further strengthened by their oral formulations, ~~ensuring~~which ensure prolonged adhesion for 12-24 ~~hours~~ hours and controlled release of the active ingredient, enhancing drug efficacy and ~~patients’~~patient outcomes – a major advancement over normal gels and creams.

~~Orocidin~~NoviThera ~~A/S~~is ~~latest~~developing ~~development~~a drug for the treatment of psoriasis, an immune-mediated inflammatory disease that causes keratinocyte hyperproliferation and inflammation.

Orocidin A/S ~~has successfully completed a 14-day toxicology study in hamsters and a test of effectiveness in a Beagle Dog Study, respectively.~~

InOrocidin ~~the~~A/S has successfully completed a 14-~~days~~day toxicology study, ~~all~~in ~~animals~~hamsters ~~exhibited high tolerance to the drug, with no adverse reactions~~ and ~~irritation~~two attests ~~the~~of ~~buccal application~~effectiveness ~~site.~~in Noa ~~significant~~Beagle ~~side~~Dog ~~effects~~Study ~~were observed~~ and ~~more importantly, the necroscopic cross examination showed no changes~~Wistar inRat ~~tissues~~Study. ~~The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study.~~

~~The~~In ~~Beagle~~the ~~Dog~~14-day ~~Study~~toxicology isstudy, ~~the~~all ~~first~~animals ~~study~~exhibited ~~that~~high ~~shows~~tolerance ~~Orocidin~~to ~~A/S~~the drug, ~~QR-01,~~with ~~having~~no aadverse ~~direct~~reactions ~~effect~~or onirritation ~~periodontitis~~at ~~diagnosed~~the ~~beagle~~buccal application ~~dogs~~site. ~~The~~ ~~13-day~~No ~~small~~significant ~~efficacy~~side ~~study~~effects ~~was~~were ~~conducted~~observed onand ~~beagle~~more ~~dogs~~importantly, ~~with~~the ~~clinically~~necropsy ~~confirmed~~cross-examination ~~periodontitis~~showed no changes in tissues. The ~~dogs~~successful ~~demonstrated~~completion ~~consistent improvements~~of ~~across~~this ~~key~~study ~~clinical~~marks ~~endpoints,~~an ~~including~~important ~~the~~milestone ~~Gingival~~for ~~Index~~Orocidin A/S, providing the ~~Plaque~~foundation ~~Index~~for ~~and~~the ~~overall~~upcoming pivotal ~~periodontal~~8-week ~~Disease~~toxicity study.

~~Moreover,~~The Beagle Dog Study is the first study that shows Orocidin A/S’s drug, QR-01, ~~was~~having ~~well~~a ~~tolerated,~~direct ~~with~~effect noon ~~adverse~~beagle ~~side~~dogs ~~effects~~diagnosed ~~reported~~with periodontitis. ~~throughout~~The ~~the~~13-day ~~treatment~~small ~~period.~~efficacy ~~This~~study ~~represents~~was aconducted ~~significant~~on ~~milestone for~~beagle ~~Orocidin’s~~dogs ~~lead~~with ~~product,~~clinically ~~QR-01,~~confirmed ~~and~~periodontitis. ~~strengthens~~The ~~Nordicus’~~dogs ~~and~~demonstrated consistent ~~Orocidin’s~~improvements ~~confidence~~across askey ~~Orocidin~~clinical ~~prepare~~endpoints, ~~for~~including the ~~upcoming~~ ~~human~~Gingival ~~pilot~~Index, ~~efficacy~~the ~~study~~Plaque Index and overall periodontal disease.

~~Bio~~Moreover, QR-~~Convert~~01 was well tolerated, with no adverse side effects reported throughout the treatment period. This represents a significant milestone ~~A/S~~for ~~latest~~Orocidin’s ~~development~~lead product, QR-01, and strengthens Nordicus’ and Orocidin’s confidence as Orocidin prepares for the upcoming human pilot efficacy study.

~~Bio-Convert~~In ~~has~~the ~~received~~second ~~positive~~efficacy ~~and~~study, ~~constructive~~rats ~~scientific~~with ~~advice~~induced ~~from~~periodontitis ~~the~~treated ~~Danish~~with ~~Medicines~~QR-01 ~~Agency~~demonstrated improvements in Probing Depth (~~DKMA~~PD-mm), ~~regarding~~Gingival Index ~~QR-02~~(GI), asBleeding aon ~~treatment~~Probing ~~for~~(BOP) ~~oral leukoplakia.~~and ~~DKMA’s~~Plaque ~~feedback~~Levels ~~paves~~(PL). ~~the~~More ~~way~~importantly, ~~toward~~lower abone ~~First~~loss inwas ~~Human~~demonstrated ~~trial,~~in ~~with~~treated arats ~~high~~compared to ~~likelihood~~non-treated ofrats ~~animal~~measured ~~studies~~by ~~rendered~~micro-CT ~~dispensable for~~scanning. ~~the~~Until ~~proposed~~now, ~~formulation~~this ~~and~~has ~~route~~not ofbeen ~~application~~demonstrated.

In summary, Orocidin has now demonstrated efficacy in treating periodontitis in two different animals using two methods. The first Phase IIa clinical trial in patients is now anticipated to start in the first half of 2027 at the University of Copenhagen in Denmark.

Bio-Convert

Bio-Convert’s QR-02 compound targets oral leukoplakia (OLK), which consists of potentially pre-cancerous lesions in the mouth, with up to a 30% conversion rate to oral cancer. No approved medical treatment exists for OLK, with surgery the only true alternative.

The company’s proprietary oral gel QR-02 has several unique advantages, including antitumor and antiviral effects, reducing the risk of dysplasia and enabling more precise and efficient treatment, compared to methods used today.

Bio-Convert obtained a toxicity waiver from the Danish Medicine Agency (DKMA) for QR-02 and is currently finalizing its GMP (Good Manufacturing Practice) product, expected to be completed by December 2026 in Germany. Bio-Convert anticipates moving into Phase IIa clinical trials in Europe beginning in the first half of 2027.

NoviThera

NoviThera’s QR-04 compound has the goal of developing a novel monoclonal antibody treatment designed to cure psoriasis or prevent its occurrence. Currently, no permanent cure for psoriasis exists, leading to a significant unmet medical need for patients and substantial market potential.

NoviThera recently completed a study in mice, and with such study demonstrated biological proof of concept.

Item 1A. Risk Factors

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

Item 1B. Unresolved Staff Comments

None.

Item 1C. Cybersecurity

We use, store and process data for and about our ~~customers,~~ employees, partners and suppliers. We have implemented a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats to this data, our systems and business operations.

Cyber Risk Management and Strategy

Under the oversight of the ~~Board~~Audit ofCommittee ~~Directors,~~(and ~~since~~before weits docreation ~~not~~in ~~currently~~November ~~have~~2025, anthe ~~Audit~~full ~~Committee~~Board of Directors), we have implemented and maintain a risk management program that includes processes for the systematic identification, assessment, management, and treatment of cybersecurity risks.

We utilize third parties and consultants to assist in the identification and assessment of risks, including to support tabletop exercises and to conduct security testing, if deemed necessary. We utilize well-known cloud-based technologies and service providers such as Microsoft Office, and Google ~~enterprise~~Enterprise to provide protection against cybersecurity threats.

We continue to evaluate and enhance our systems, controls, and processes where possible, including in response to actual or perceived threats specific to us or experienced by other companies.

Risks from cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition.

Item 2. Properties

None.

Item 3. Legal Proceedings

We are not the subject of any pending legal proceedings;, and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is ~~party~~a party to any action in which ~~any~~such person has an interest adverse to us.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Effective August 1, 2020, we voluntarily downgraded from the OTCQB Market to the OTC PINK tier of the OTC Markets. On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD. On May 9, 2024, we relisted on the OTCQB Market. In September 2025 we applied to uplist to the Nasdaq Capital Market and are awaiting final approval.

Our shares are subject to Section 15(g) and Rule 15g-9 of the Securities and Exchange Act, commonly referred to as the “penny stock” rule. The rule defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. These rules may restrict the ability of broker-dealers to trade or maintain a market in our common stock and may affect the ability of shareholders to sell their shares. Broker-dealers who sell penny stocks to persons other than established customers and accredited investors must make a special suitability determination for the purchase of the security. Accredited investors, in general, include individuals with assets in excess of $1,000,000 (not including their personal residence) or annual income exceeding $200,000 or $300,000 together with their spouse, and certain institutional investors. The rules require the broker-dealer to receive the purchaser’s written consent to the transaction prior to the purchase and require the broker-dealer to deliver a risk disclosure document relating to the penny stock prior to the first transaction. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, and current quotations for the security. Finally, monthly statements must be sent to customers disclosing recent price information for the penny stocks.

Holders

As of July 1614, ~~2025~~2026, there were approximately ~~217~~405 stockholders of record of our common stock, although we believe that there are other persons who are beneficial owners of our common stock held in street name. The transfer agent and registrar for our common stock is Transfer Online, 512 SE Salmon Street, Portland, OR 97214. Their telephone number is (503) 227-2950.

Dividends

We have not paid cash or stock dividends and have no present plan to pay any dividends, intending instead to reinvest our earnings, if any. For the foreseeable future, we expect to retain any earnings to finance the operation and expansion of our business and the payment of any cash dividends on our common stock is unlikely.

Recent Sales of Unregistered Securities

On May 23, 2024, the Company entered into an agreement with FORCE Family ~~office~~Office for the provision of consulting services, for a fee consisting of 30,000 restricted shares of the Company’s common stock.

On May 13, 2024, the Company ~~and~~acquired ~~certain~~a ~~shareholders~~95.0% ofinterest in Orocidin A/S (~~the~~ “Orocidin ~~Sellers~~”), a Danish ~~stock~~preclinical-stage ~~corporation (“Orocidin”)~~biotechnology ~~entered~~company ~~into~~advancing anext-generation ~~Stock~~periodontitis ~~Purchase and Sale Agreement (the “Agreement”)~~therapies, ~~under~~in ~~which the Orocidin Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock. In~~ exchange, ~~the~~for ~~Company issued~~ 3,800,000 restricted shares of ~~its common stock to~~ the ~~Orocidin~~Company’s ~~Sellers. The~~common ~~transaction was consummated on May 13, 2024~~stock. ~~Orocidin A/S, is a preclinical-stage biotechnology company which is advancing the next generation of periodontitis therapies.~~

On November 11, 2024, the Company announced that it had entered into an agreement ~~with Bio-Convert A/S (“Bio-Convert”)~~ to acquire 100% of the outstanding shares of Bio-Convert A/S ~~in exchange for 12,000,000 restricted shares of the Company’s common stock.~~ (“Bio-Convert is”), a Denmark-based preclinical-stage biotechnology company ~~aiming~~developing totreatments ~~revolutionize~~for ~~the treatment of~~ oral leukoplakia ~~by minimizing or~~, ~~removing oral leukoplakia lesions~~ in ~~order~~exchange tofor ~~further~~12,000,000 ~~reduce~~restricted ~~the~~shares ~~risk~~ of ~~such lesions resulting in~~ the ~~development~~Company’s ofcommon ~~oral cancer in patients~~stock.

7On November 12, 2024, the Company acquired the remaining 29,663 outstanding shares, or approximately 5%, of Orocidin A/S in exchange for 200,000 restricted shares of the Company’s common stock, after which Orocidin A/S became a wholly owned subsidiary of the Company.

On November 1227, 2024, the Company entered into ana ~~agreement~~Professional ~~with~~Relations ~~Orocidin~~and ~~A/S~~Consulting toAgreement ~~acquire~~with ~~the~~ESG ~~remaining~~Advisor 29Group,~~663~~ ~~outstanding~~L.L.C. ~~shares,~~(“ESG”) for orthe ~~approximately 5%,~~provision of ~~Orocidin~~investor ~~A/S~~relations and related services. InThe ~~exchange,~~term of the ~~Company~~agreement ~~issued~~was ~~200,000~~to ~~shares~~expire ofon ~~restricted~~November ~~common~~30, ~~stock~~2025, subject to termination ~~the~~by ~~selling~~either ~~shareholders~~party ofafter ~~Orocidin~~three months on 30 days’ prior notice. On January 15, 2025, the Company elected to terminate ~~Upon~~the ~~closing~~agreement as of ~~the~~February ~~acquisition~~27, ~~Orocidin~~2025. ~~A/S~~Under ~~became~~the aagreement, ~~100%~~ESG ~~wholly~~was ~~owned~~entitled ~~subsidiary~~to receive 19,500 shares of ~~the~~restricted ~~Company~~common stock, which were issued on January 23, 2025.

On November 27, 2024, the Company entered into a Professional Relations and Consulting Agreement with ESG Advisor Group, L.L.C. (“ESG”) for the provisions of investor relations and related services. The term of the Agreement was to expire on November 30, 2025, subject to termination by either party after three months on 30 days’ prior notice. On January 15, 2025, the Company elected to terminate the agreement as of February 27, 2025. Under the agreement, ESG was entitled to receive 19,500 shares of restricted common stock, which were issued on January 23, 2025.

Effective April 1, 2022, we issued to GK Partners ApS (“GK Partners”) , for financial services, a warrant (the “2022 GK Warrant”) to purchase up to 600,000 shares of our Common Stock at an exercise price of $10.00 per share, and which had an expiration date of December 31, 2023. The Company determined that the 2022 GK Warrant is not precluded from equity classification and was therefore recorded within additional paid-in capital on the Company’s consolidated balance sheets at its issuance date fair value. On December 22, 2023, the expiration date of the warrant, covering 570,500 remaining unexercised warrant shares, was extended to December 31, 2024. During the year ended March 31, 2024, GK Partners exercised a portion of its warrant for a total of 30,600 shares. The exercise price was $10.00 per share for total proceeds of $306,000. For the year ended March 31, 2025, GK Partners exercised a portion of its warrant for 57,400 shares. The exercise price was $10.00 per share for total proceeds of $576,000. On December 31, 2024 the 2022 GK Warrant expired.

Effective December 30, 2024, a new warrant was issued to GK Partners (the “2024 GK Warrant”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price equal to the greater of $8.91 and the daily volume weighted average price of the Common Stock for the ten trading days immediately preceding the date of exercise. The 2024 GK Warrant expires on December 31, 2025. The Company determined that the 2024 GK Warrant was precluded from being classified within equity and was liability classified under ASC Topic 815, Derivatives and Hedging. During the year ended March 31, 2025, GK Partners exercised a portion of its 2024 GK Warrant for a total of 35,176 shares. The exercise price ranged from $8.91 to $8.95 per share for total proceeds of $313,455. As of March 31, 2025, the 2024 GK Warrant was terminated. Therefore, as of March 31, 2025, the Company recognized no warrant liability on the consolidated balance sheet. The measurement of fair value of the 2024 GK Warrants was determined utilizing a Monte Carlo Simulation model considering all relevant assumptions current as of March 31, 2025 presented in Note 6. The change in fair value resulting from the issuance of 2024 GK Warrant was recognized in change in fair value of warrant liability (related party) in the amount of $172,715 on the consolidated statement of operations and comprehensive loss for the year ended March 31, 2025. On March 31, 2025, the 2024 GK Warrants were terminated and remaining shares were recorded to a fair value of $167,000 to additional paid in capital at due to the related party relationship.

Issuer Purchase of Securities

We did not repurchase any of our securities during our fiscal year ended March 31, 2025.

~~Securities~~Effective ~~Authorized~~December 30, 2024, a new warrant was issued to GK Partners (the “2024 GK Warrant”) to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price equal to the greater of $8.91 and the daily volume weighted average price of the common stock for ~~Issuance~~the ten trading days immediately preceding the date of exercise. The 2024 GK Warrant expired on December 31, 2025. The Company determined that the 2024 GK Warrant was precluded from being classified within equity and was liability classified under ~~Equity~~ASC ~~Compensation~~Topic ~~Plans~~815, Derivatives and Hedging. During the year ended March 31, 2025, GK Partners exercised a portion of its 2024 GK Warrant for a total of 35,176 shares. The exercise price ranged from $8.91 to $8.95 per share for total proceeds of $313,455. As of March 31, 2025, the 2024 GK Warrant was terminated. Therefore, as of March 31, 2026, the ~~End~~Company recognized no warrant liability on the consolidated balance sheet. The measurement of ~~Fiscal~~fair value of the 2024 GK Warrants was determined utilizing a Monte Carlo simulation model considering all relevant assumptions current as of March 31, 2026 presented in Note 6. The change in fair value resulting from the issuance of the 2024 GK Warrant was recognized in change in fair value of warrant liability (related party) in the amount of $172,715 on the consolidated statement of operations and comprehensive loss for the year ended March 31, 2025. On March 31, 2025, the 2024 GK Warrants were terminated, and the remaining shares were recorded at a fair value of $167,000 to additional paid in capital due to the related party relationship.

In October through March 2026, we issued to private investors a total of 1,850,036 restricted shares of our common stock, par value $0.001 per share. The purchase price ranged from $1.90-5.00 per share,

The shares of common stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdiction’s securities laws.

We claim an exemption from registration for the issuance of the shares pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) and (c) of Regulation D thereunder, since the foregoing issuances did not involve a public offering, each recipient was (i) an “accredited investor” and/or (ii) had access to similar documentation and information as would be required in a registration statement under the Securities Act, and each such recipient represented that it acquired the securities for investment only and not with a view toward, or for resale in connection with, the public sale or distribution thereof. The securities were offered without any general solicitation by us or our representatives. No underwriters or agents were involved in the foregoing issuances, and we paid no underwriting discounts or commissions. The shares are subject to transfer restrictions, and the certificates evidencing the securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom. The issuance of the shares was also exempt under Regulation S under the Securities Act as the offering was made to non-U.S. persons, was made with no directed selling efforts in the U.S. and otherwise was made in accordance with the requirements of the Securities Act.

On March 13, 2026, the Company entered into an agreement with an unaffiliated party for the provision of consulting services for a fee consisting of 60,000 restricted shares of the Company’s common stock.

On March 16, 2026, the Company entered into an agreement with an unaffiliated party for the provision of consulting services for a fee consisting of 24,000 restricted shares of the Company’s common stock.

Issuer Purchase of Securities

On October 1, 2025, the Company repurchased 57,642 shares of common stock from an existing shareholder for $1.36 per share. The repurchase was made pursuant to the share repurchase program authorized by the Company’s Board of Directors.

Securities Authorized for Issuance under Equity Compensation Plans as of the End of Fiscal 2026

Equity Compensation Plan Information

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights		Weighted average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance
Equity compensation plans approved by board of directors (1)		825,000		3.25		6,175,000	(1)
Equity compensation plans approved by the Board of Directors (1)		925,000		3.00		6,075,000	(1)
		825,000	$	3.25		6,175,000
		925,000		3.00		6,075,000

(1)	All such options were issued under the Company’s 2024 Stock Incentive Plan. The Company’s 2017 Non-Qualified Equity Incentive Plan was terminated on June 17, 2024. At the time of termination, no options were outstanding under the 2017 Plan.

Stock Repurchase Plan

In June 2001, the Board of Directors adopted a share repurchase program authorizing the repurchase of up to 250,000 of our shares of common stock. In June 2004, the Board of Directors authorized the purchase of an additional 500,000 shares of common stock. ~~Since~~In August 2025, the Board of Directors authorized the purchase of an additional 200,000 shares of common stock. Since June 2001, a total of ~~251~~303,~~379~~021 shares have been repurchased by us under the share repurchase program, leaving ~~498~~646,~~621~~979 shares remaining to ~~purchase~~be purchased under the share repurchase program. NoThe ~~repurchases~~Company ~~were~~repurchased ~~made~~57,642 and zero shares during the fiscal years ended March 31, 2026 and 2025, ~~and 2024~~respectively. The share repurchase program authorizes repurchases from time to time in open market transactions, through privately negotiated transactions, block transactions or otherwise, at times and prices deemed appropriate by management, and is not subject to an expiration date.

Stockholder Rights Plan

Our Board of Directors approved the adoption of a stockholder rights plan (the “Rights Plan”) under which all stockholders of record as of February 8, 2008 ~~will~~received ~~receive~~ rights to purchase shares of a new series of preferred stock (the “Rights”). The Rights were ~~will be~~ distributed as a dividend. Initially, the Rights ~~will~~attached ~~attach~~ to, and ~~trade~~traded with, our common stock. Subject to the terms, ~~conditions~~ conditions and limitations of the Rights Plan, the Rights ~~will~~ become exercisable if (among other things) a person or group acquires 15% or more of our common stock. Upon such an event, and payment of the purchase price, each Right (except those held by the acquiring person or group) will entitle the holder to acquire shares of the Company’s common stock (or the economic equivalent thereof) having a value equal to twice the purchase price. Our Board of Directors may redeem the Rights prior to the time they are triggered. In the event of an unsolicited attempt to acquire us, the Rights Plan is intended to facilitate the full realization of our stockholder value and the fair and equal treatment of all of our stockholders. The Rights Plan will not prevent a takeover attempt. Rather, it is intended to guard against abusive takeover tactics and encourage anyone seeking to acquire us to negotiate with the Board of Directors. We did not adopt the Rights Plan in response to any particular proposal.

910

Item 6. [Reserved]

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

The ~~information~~following inManagement’s ~~this~~Discussion ~~report~~and ~~contains~~Analysis ~~forward-looking~~of ~~statements.~~Financial ~~All~~Condition ~~statements~~and ~~other~~Results ~~than~~of Operations (the “MD&A”) should be read in conjunction with our financial statements ofand ~~historical~~the ~~fact~~related ~~made~~notes thereto included elsewhere in this ~~report~~ ~~are~~Annual ~~forward looking~~Report. InThe ~~particular,~~MD&A contains ~~the~~forward-looking statements ~~herein~~that ~~regarding~~involve ~~industry~~risks ~~prospects~~ and ~~future~~uncertainties, ~~results~~such as statements of ~~operations~~our orplans, objectives, expectations, ~~financial~~and ~~position~~intentions. Any statements that are ~~forward-looking~~not statements. ~~These~~of historical fact are forward-looking statements. ~~can~~When beused, ~~identified by~~ the ~~use of~~ words ~~such as~~“believe,” “~~believes~~plan,” “~~estimates~~intend,” “~~could~~anticipate,” “~~possibly~~target,” “~~probably~~estimate,” ~~anticipates,”~~ “~~projects~~expect,” and the like, and/or future-tense or conditional constructions (“~~expects~~will,” “may,” “~~will~~could,” or “should,” or ~~other~~etc.), ~~variations~~ or similar ~~words.~~expressions, Noidentify ~~assurances~~certain ~~can~~of bethese ~~given that the future results anticipated by the~~ forward-looking statements ~~will be achieved~~. ~~Forward~~These forward-looking statements ~~reflect management’s current expectations and~~ are ~~inherently~~subject ~~uncertain. If~~to ~~underlying assumptions prove inaccurate or unknown~~ risks orand uncertainties ~~materialize,~~that ~~our~~could cause actual results ~~may~~or ~~differ~~events ~~significantly from~~to ~~management’s~~differ ~~expectations.~~materially ~~Should~~from ~~one~~those orexpressed ~~more of these risks~~ or ~~uncertainties~~implied ~~materialize,~~by orthe ~~should~~forward-looking statements ~~any~~in ofthis ~~our assumptions~~Annual ~~prove~~Report. ~~incorrect,~~Our actual results ~~may~~and ~~vary~~the intiming ~~material~~of ~~respects~~events could differ materially from those anticipated in these ~~forward-looking~~ ~~statements. The Company undertakes no obligation to update or revise any~~ forward-looking statements, ~~whether~~ as a result of ~~new information~~several factors including, ~~future~~but ~~events~~not orlimited ~~otherwise~~to, ~~except~~those asnoted ~~may~~under be“Risk ~~required~~Factors” in ~~under~~this ~~applicable~~Annual ~~securities laws~~Report.

We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report, except as required by U.S. federal securities laws.

Overview

Nordicus Partners Corporation is a U.S. publicly listed ~~business~~biotech ~~accelerator and holding~~ company ~~dedicated~~specializing ~~to helping Nordic life sciences companies succeed~~ in ~~the~~developing ~~American~~breakthrough ~~market.~~therapeutics Byfor ~~combining~~diseases ~~Nordic innovation~~ with ~~U.S. operational expertise, Nordicus Partners Corporation creates~~ ~~a distinct advantage in identifying, scaling, and exiting high-potential companies in fast-growing markets with~~ unmet medical needs. Current portfolio companies include the ~~two~~three promising preclinical biotechnology companies Orocidin A/S, ~~and~~ Bio-Convert A/S and NoviThera ApS.

Organizational History Summary

WeOur ~~were~~detailed ~~founded~~corporate inhistory ~~1993~~is ~~and~~described in ~~2007~~Item ~~were~~1. ~~reincorporated~~In ~~from~~summary, aafter ~~Massachusetts~~our ~~corporation~~pre-2021 tohistory as a Delaware corporation. Weunder ~~changed~~prior ~~our name~~names, ~~from~~the ~~CardioTech~~Company ~~International,~~underwent ~~Inc.~~a tochange-of-control ~~AdvanSource~~transaction ~~Biomaterials~~with ~~Corporation,~~Reddington ~~effective~~Partners LLC beginning in October 152021, ~~2008.~~completed Onreverse stock splits in March 3,2022 ~~2020~~and November 2024, weacquired NP Bioinnovation A/S in February 2023, changed ~~our~~ its name to ~~EKIMAS~~Nordicus Partners Corporation and ticker symbol to NORD in May 2023, acquired Orocidin A/S and Bio-Convert A/S in 2024, formed NoviThera ApS in October 2025 and expanded its board and governance committee structure in 2025.

On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company(“Reddington”) providing for the purchase of a total of 5,114,475 shares of our common stock, on a post-split basis, or approximately 90% of our total shares of common stock outstanding for total cash consideration of $400,000. Reddington purchased the common stock in two tranches on October 12, 2021 (the “First Closing”) and March 15, 2022.

Pursuant to the SPA, the Company effectuated a 1-for 50 reverse stock split on March 11, 2022 (the “Reverse Split”). Accordingly, on a post-split basis, the shares purchased in connection with the First Closing resulted in Reddington owning 42,273 shares of our common stock. As set forth in the SPA, Reddington then purchased from us on March 15, 2022, an additional 469,175 shares of our common stock, on a post-split basis (the “Second Closing”). After the issuance thereof Reddington owned 511,448 shares of our common stock, or approximately 90% of our total shares of common stock outstanding.

On February 23, 2023, the Company and NP Bioinnovation A/S (formerly Nordicus Partners A/S and Managementselskabet af 12.08.2020 A/S), a Danish stock corporation, consummated the transactions contemplated by a certain contribution agreement (the “Contribution Agreement”) by and among the Company, NP Bioinnovation A/S, GK Partners ApS (“GK Partners”), Henrik Rouf and Life Science Power House ApS (“LSPH”) (GK Partners, Rouf and LSPH are collectively referred to herein as the “Sellers”, and each individually as a “Seller”). Pursuant to the Contribution Agreement the Sellers contributed, transferred, assigned and conveyed to the Company all right, title and interest in and to one hundred percent (100%) of the issued and outstanding capital stock of NP Bioinnovation A/S for an aggregate of 250,000 shares of the Company’s Common Stock, par value $0.001 per share. As a result of this transaction, NP Bioinnovation A/S became a 100% wholly owned subsidiary of the Company.

On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company.

On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD.

On June 1, 2023, the Company acquired a 4.99% interest in Mag Mile Capital, Inc., a full-service commercial real estate mortgage banking firm headquartered in Chicago with offices in the states of New York, Massachusetts, Connecticut, Florida, Texas and Nevada. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the full capital stack and across all major real estate asset classes nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneurs.

On June 9, 2023, Mr. Tom Glaesner Larsen resigned as a director of the Company and Henrik Keller was appointed as his replacement.

On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement.

On November 8, 2024, the Company effectuated a 1-for-10 reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the “Reverse Stock Split”). The Reverse Stock Split had no effect on the Company’s authorized shares of common stock or preferred stock and the par value will remain unchanged at $0.001, respectively. All common stock share, option, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these unaudited consolidated financial statements and related disclosures.

On November 12, 2024, the Company entered into an agreement with Orocidin A/S to acquire the remaining 29,663 outstanding shares, or approximately 5%, of Orocidin A/S. In exchange, the Company issued 200,000 shares of restricted common stock to the selling shareholders of Orocidin. Upon closing of the acquisition, Orocidin A/S became a 100% wholly owned subsidiary of the Company.

Our Business

~~Since the current leadership assumed control of~~ Nordicus Partners Corporation (“Nordicus” or the “Company”), ~~the~~is ~~Company has evolved into~~ a ~~leading~~ U.S. publicly listed ~~business~~biotech ~~accelerator~~company specializing in developing breakthrough therapeutics for diseases with unmet medical needs. Nordicus focuses on acquiring and ~~holding~~developing ~~company~~drugs ~~dedicated~~from toinnovative biotech ~~helping~~companies ~~Nordic~~in the Nordics, a region known for its scientists, life sciences ~~companies~~ecosystem and drug discoveries and developments. Nordicus ~~succeed~~is dedicated to developing breakthrough therapeutics in ~~the~~diseases ~~American~~with ~~market.~~unmet Bymedical ~~combining~~needs ~~Nordic~~– ~~innovation~~starting with Uoral disorders.S Its scientific foundation targets inflammation and immune modulation. ~~operational~~In ~~expertise~~2024, Nordicus ~~Partners~~acquired ~~Corporation~~100% ~~creates~~ of Orocidin A/S, a ~~distinct~~Danish ~~advantage~~preclinical-stage inbiotech company ~~identifying,~~developing ~~scaling,~~next-generation therapies for periodontitis and ~~exiting~~100% ~~high~~of Bio-~~potential~~Convert ~~companies~~A/S, ina ~~fast~~Danish preclinical-~~growing~~stage ~~markets~~biotech ~~with~~company dedicated ~~unmet~~to ~~medical~~developing ~~needs~~treatments for oral leukoplakia.

Nordicus’ portfolio diversification strategy positions us as a stable and resilient company, mitigating risk with significant upside potential.

Our Approach and Value Creation Process

Nordicus employs a 4-step value creation process:

– Scout and Accelerate: Nordicus targets high-impact potential companies, providing capital, resources and expertise to drive critical milestones such as patent filings and clinical trials. ~~– Acquire and Exit: Nordicus acquires controlling stakes to maximize value creation and exit at premium multiples.~~

–

Acquire and Exit: Nordicus acquires controlling stakes to maximize value creation and exit at premium multiples.

Nordicus aims to take all portfolio companies’ drug developments through Phase I. Upon completion of Phase I, the following options will be considered:

1. Sale or merger of the portfolio company. 2. Further development through the next clinical phases. 3. Strategic partnership with a large pharmaceutical company that will invest in Nordicus for further drug development. 4. Stand-alone Initial Public Offering (IPO).

~~Nordicus’ current~~2 ~~life~~Further ~~sciences~~development ~~portfolio~~through ~~consists of two promising preclinical biotechnology companies in Orocidin A/S and Bio-Convert A/S led by~~ the ~~accomplished~~next ~~pharmacologist,~~clinical ~~Allan Wehnert, who serves as CEO of both companies~~phases.

Strategic partnership with a large pharmaceutical company that will invest in Nordicus for further drug development.

Stand-alone Initial Public Offering (IPO).

Nordicus’ current life sciences portfolio consists of two promising preclinical biotechnology companies, Orocidin A/S and Bio-Convert A/S, led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of both companies. In October 2025, the Company formed a third subsidiary, NoviThera, also led by Alan Wehnert.

Orocidin A/S ~~has successfully completed a 14-day toxicology study in hamsters and a test of effectiveness in a Beagle Dog Study, respectively.~~

InOrocidin ~~the~~A/S has successfully completed a 14-~~days~~day toxicology study, ~~all~~in ~~animals~~hamsters ~~exhibited high tolerance to the drug, with no adverse reactions~~ and ~~irritation~~two attests ~~the~~of ~~buccal application~~effectiveness ~~site.~~in Noa ~~significant~~Beagle ~~side~~Dog ~~effects~~Study ~~were observed~~ and ~~more~~a ~~importantly, the necroscopic cross examination showed no changes~~Wistar inRat ~~tissues~~Study. ~~The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study.~~

Bio-Convert

NoviThera

NoviThera’s QR-04 compound has the goal to develop a novel anti-monoclonal antibody treatment designed to cure psoriasis or prevent its occurrence. Currently, no permanent cure for psoriasis exists, leading to a significant unmet medical need for patients and huge market potential.

NoviThera recently completed a study in mice, and with such study demonstrated biological proof of concept.

Results of Operations

Fiscal Year Ended March 31, ~~2025~~2026 Compared to the Fiscal Year Ended March 31, ~~2024~~2025

Revenue

During the year ended March 31, ~~2025~~2026, we had no revenue relating to consulting income ~~of $5,000~~ compared to $25,~~500~~000 for the year ended March 31, ~~2024~~ 2025, a andecrease ~~increase~~ of $25,~~500~~000 or 100%.

Operating Expenses

During the year ended March 31, ~~2025~~2026, we had officer compensation expense of $~~662~~615,~~554~~284 compared to $~~118~~662,~~477~~554 for the year ended March 31, ~~2024~~2025, ana ~~increase~~decrease of $~~544~~47,~~077~~270 or ~~459~~7%. This ~~increase~~decrease was primarily due to anstock-based ~~increase~~compensation for board members in ~~salaries~~November ~~for~~2024, ~~and~~partially offset by an ~~issuance~~increase ofin ~~stock~~salaries ~~options~~for to the Company’s chief executive officer and chief financial officer asin ~~well~~July ~~as increased compensation for and an issuance of stock options to the members of the Company’s Board of the Directors~~2025. See Note 5 to our accompanying consolidated financial statements for more information on these ~~transaction~~transactions.

For the year ended March 31, ~~2025~~2026, we had professional fees of $~~351~~940,~~773~~727 compared to $~~137~~351,~~280~~773 for the year ended March 31, ~~2024~~2025, an increase of $~~214~~588,~~493~~954 or ~~156~~167%. The increase iswas ~~largely~~primarily due to increased legal and accounting expenses related to the acquisition of NoviThera during the year ended March 31, 2026 and accounting and legal expenses for prior acquisitions of ~~Orocidin~~Orodicin and Bio- Convert.

For the year ended March 31, ~~2025~~2026, we had consulting expense of $~~248~~317,~~878~~960 compared to ~~zero~~$248,878 expense for the year ended March 31, ~~2024~~2025, an increase of $~~248~~69,~~878~~082 or 28%. The increase is due to ~~fees paid to new members of Orocidin’s advisory board as well as~~ the issuance of ~~Common Stock and~~ restricted stock units to a third ~~parties~~party as compensation for consulting services rendered during the year ended March 31, ~~2025~~2026 ~~that did~~related ~~not~~to ~~occur~~our ~~during~~Nasdaq ~~the~~uplist ~~year ended March 31, 2024~~application.

For the year ended March 31, 2025, we had general and administrative expenses (“G&A”) of $331,724 compared to $54,331 for the year ended March 31, 2024, an increase of $277,393 or 511%. The increase in G&A expense is attributable to increased travel expenses as well as increased SEC and other regulatory filing fees related to the acquisitions of Orocidin and Bio-Convert. In addition, there was an increase in costs related to directors and officers insurance resulting from the expansion of the business.13

For the year ended March 31, ~~2025~~2026, we had ~~research~~general and ~~development~~administrative ~~expense~~expenses (“G&A”) of $1890,~~329,436~~055 compared to ~~zero~~$331,724 for the year ended March 31, ~~2024~~2025, an increase of $1558,~~329,436~~331 or 168%. The increase isin ~~due~~G&A toexpense ~~research~~is ~~and~~attributable ~~development~~to ~~costs~~increased ~~incurred~~staff bysalaries along ~~Orocidin~~with ~~and~~the ~~Bio-Convert~~addition ~~subsequent~~of toadditional ~~the acquisition~~administrative ofassistance, ~~each~~a ~~entity~~media ~~during~~advisor, ~~the~~and ~~year~~an ~~ended~~increase ~~March~~in ~~31,~~costs ~~2025~~related ~~that~~to ~~did~~directors ~~not~~and ~~occur~~officers insurance ~~during~~resulting from the ~~year~~expansion ~~ended~~of ~~March~~the ~~31, 2024~~business.

For the year ended March 31, 2026, we had research and development expense of $1,606,972 compared to $1,329,436 for the year ended March 31, 2025, an increase of $277,536 or 21%. The increase was primarily driven by increased operations of NoviThera, which was formed during the year ended March 31, 2026, and by increased activities of NP Bioinnovation A/S. Both subsidiaries contributed a full year of operations following their respective acquisitions, with activities focused on advancing Orodicin and Bio Convert.

Other (Expense) Income

For the year ended March 31, ~~2025~~2026, we ~~had~~recorded $2324,~~085~~194 of other income compared to ~~other income of~~ $92,~~386~~085 for the year ended March 31, ~~2024~~2025 due to changes in fair value of investments.

~~For~~Other ~~the~~Comprehensive ~~year~~Income ended March 31, 2025, we recorded a loss of $172,715 on the change in fair value of its liability classified warrants issued to a related party and a gain of $175,000 on the change in fair value of investments. The Company did not record a gain or loss related to the fair value of warrants for year ended March 31, 2024 as there were no liability classified warrants issued during the year ended March 31, 2024.(Loss)

For the year ended March 31, 2026, we recorded a gain of $3,699,514 on foreign currency translation adjustments compared to a gain of $618,233 for the year ended March 31, 2025. The increase is primarily driven by the strengthening of the Danish Krone against the U.S. Dollar by approximately 6.15% from March 31, 2025 to March 31, 2026, which increased the U.S. Dollar value of our DKK-denominated net assets upon translation.

Liquidity and Capital Resources

~~During~~In ~~the~~August ~~year~~2025, ~~ended~~our ~~March~~Board ~~31,~~of ~~2025,~~Directors weauthorized ~~used~~a ~~$1,284,615~~share inrepurchase ~~operating~~program ~~activities~~which ~~compared~~permits us to ~~$258~~repurchase up to an aggregate of 200,~~928~~000 shares ~~used~~of our Common Stock from existing shareholders only, solely in ~~operating~~privately ~~activities~~negotiated ~~during~~transactions, ~~the~~at a purchase price per share ~~year~~not ~~ended~~greater ~~March~~than ~~31,~~the ~~2024.~~then-current ~~This~~market ~~increase~~price isas ~~primarily~~determined ~~due~~based on the last reported sale price of our Common Stock on our principal trading market. We are not obligated to repurchase any shares and may suspend or terminate the ~~significant~~program ~~increase~~at inany ~~operating~~time. ~~expenses~~Repurchased ~~incurred~~shares may be held as treasury stock or retired, as ~~detailed~~determined by management. The repurchase program will remain in effect until the earliest of (i) the ~~preceding~~repurchase ~~section~~of 200,000 ~~partially~~shares, ~~offset~~(ii) by12 ~~net~~months ~~noncash~~from ~~operating~~the ~~activity~~date ofthe ~~$669,493~~program ~~and~~was ~~increases~~authorized, inor ~~accounts~~(iii) ~~payable~~revocation ~~and~~by ~~accrued~~further ~~expenses~~Board action. On October 1, 2025, the Company repurchased 57,642 shares of Common Stock from an existing shareholder for $1.36 per share. The repurchase was made pursuant to the share repurchase program authorized by the Company’s Board of Directors. Following the transaction,~~032~~ 646,~~045~~979 shares remain authorized for repurchase.

~~During~~In ~~the~~September ~~year ended March 31,~~ 2025, we ~~had~~applied ~~$147,812~~to ~~provided~~uplist byits ~~investing~~common ~~activities~~stock ~~compared~~ to nothe ~~cash~~Nasdaq ~~used~~Capital inMarket or(“Nasdaq”). ~~provided~~Pending ~~by investing activities during~~ the ~~year~~requisite ~~ended March 31~~approvals, the ~~2024.~~Company ~~This~~will ~~cash~~endeavor ~~provided~~to byraise ~~investing~~capital ~~activities~~through ~~during~~ the ~~year~~sale ~~ended~~of ~~March~~its ~~31,~~common ~~2025~~stock ~~resulted from~~on ~~cash~~terms ~~acquired~~available into ~~the~~entities ~~acquisitions~~listed ofon ~~Orocidin~~the ~~and Bio-Convert~~Nasdaq.

During the year ended March 31, 2026, we used cash of $4,324,775 in operating activities compared to $1,284,615 used in operating activities during the year ended March 31, 2025. This increase is primarily due to the increase in net loss of $1,129,524, as detailed in the preceding section, and decreases in changes in assets and liabilities of $1,365,407, and net noncash operating activity of $545,229.

During the year ended March 31, 2026, we had net cash used in investing activities of $10,158 compared to $147,812 provided by investing activities during the year ended March 31, 2025. The decrease was primarily attributable to no acquisitions in the current year in which the Company obtained cash.

During the year ended March 31, 2026, we received $4,335,448 from financing activities primarily related to issuance of common stock. During the year ended March 31, 2025, we received $1,079,927 from financing activities primarily related to proceeds from the issuance of common stock and the exercise of warrants.

During the year ended March 31, 2025, we received $1,079,927 from financing activities primarily related to cash received from the exercise of warrants and proceeds from Orocidin’s issuance of common stock in a capital raise. During the year ended March 31, 2024, we received $306,000 from financing activities from the exercise of warrants.

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of our operations is based on our consolidated financial statements and accompanying notes, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain amounts included in or affecting the consolidated financial statements presented in this Form 10-K and related disclosure must be estimated, requiring management to make assumptions with respect to values or conditions ~~which~~that cannot be known with certainty at the time the consolidated financial statements are prepared. Management believes that the accounting policies set forth below comprise the most important “critical accounting estimates” for the Company. Management evaluates such estimates on an ongoing basis, based upon historical results and experience, consultation with experts and other methods that management considers reasonable in the particular circumstances under which the judgments and estimates are made, as well as management’s forecasts as to the manner in which such circumstances may change in the future.

Indefinite-lived Intangible Assets

We account for indefinite-lived intangible assets in accordance with ASC Topic 350, Intangibles - Goodwill and Other (“ASC 350”). Indefinite-lived intangible assets (e.g. IPR&D), are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change ~~which~~that indicate that an asset might be impaired. Pursuant to ASC 350, we test indefinite-lived intangible assets for impairment by comparing their fair values to their carrying values. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, probability-adjusted development and commercialization assumptions, discount rates and other market participant assumptions. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values.

Fair Value of Financial Instruments

We follow paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of our financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of our financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1:	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

Level 2:	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

Level 3:	Pricing inputs that are generally unobservable inputs and not corroborated by market data.

Business Combinations

We account for business combinations under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the consolidated financial statements from the acquisition date.

Goodwill

We assess goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. We regularly monitor current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing our annual goodwill impairment test, we are permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of our reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, we consider certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. We are also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If we choose to undertake the qualitative assessment and conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we would then proceed to the quantitative impairment test. In the quantitative assessment, we compare the fair value of the reporting unit to its carrying amount, which includes goodwill. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, operating results, probability-adjusted cash flows, discount rates and other market participant assumptions. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded. We assess goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.

We assess goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. We did not record an impairment charge during the year ended March 31, 2025.

Off-Balance Sheet Arrangements

As of March 31, ~~2025~~2026, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 8. Financial Statements and Supplementary Data

NORDICUS PARTNERS CORPORATION

TABLE OF CONTENTS

Report of Independent Registered Public Accounting Firm (PCAOB ID 5525)	F-1
Consolidated Balance Sheets as of March 31, 2025 and 2024	F-3
Consolidated Balance Sheets as of March 31, 2026 and 2025	F-2
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended March 31, 2025 and 2024	F-4
Consolidated Statements of Operations and Comprehensive Income (Loss) for the Years Ended March 31, 2026 and 2025	F-3
Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended March 31, 2025 and 2024	F-5
Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended March 31, 2026 and 2025	F-4
Consolidated Statements of Cash Flows for the Years Ended March 31, 2025 and 2024	F-6
Consolidated Statements of Cash Flows for the Years Ended March 31, 2026 and 2025	F-5
Notes to the Consolidated Financial Statements	F-76

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and ~~Shareholders~~Stockholders of Nordicus Partners Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Nordicus Partners Corporation and Subsidiaries (“the Company”) as of March 31, ~~2025~~ 2026 and ~~2024~~2025, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended March 31, ~~2025~~2026, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, ~~2025~~2026 and ~~2024~~2025, and the results of its operations and its cash flows for each of the years in the two-year ~~period~~ period ended March 31, ~~2025~~2026, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has nominal revenue and has incurred losses since inception resulting in an accumulated deficit. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

FImpairment Analysis for In-1Process R&D & Goodwill – Refer to Note 2 to the financial statements

Goodwill Valuation – Refer to Note 2 to the financial statements

Description of the Critical Audit Matter

~~During~~The ~~the year under audit, the~~ Company ~~acquired~~records ~~two,~~material ~~wholly~~In-Process ~~owned~~R&D ~~subsidiaries:~~and ~~Orocidin~~Goodwill ~~A/S~~balances ~~and~~as ~~Bio-Convert~~a ~~A/S~~result ~~through~~of ~~equity~~the ~~issuances pursuant~~acquisition toof ~~ASC~~two ~~805~~subsidiaries ~~Business~~during ~~Combinations.~~prior periods. We determined such transactions to be material to the financial statements and involve subjective auditor judgement in ~~determining~~evaluating the ~~valuation of assets acquired and liabilities assumed, especially for the excess of consideration~~ ~~paid~~Company’s ~~over~~impairment ~~the~~analyses ~~net~~as ~~assets and valuation~~ of ~~intangible assets~~yearend. Therefore, we determined these transactions are critical audit matters.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to evaluating the Company’s ~~accounting~~impairment ~~for~~analyses ~~the~~of ~~valuation~~its ofindefinite-lived in-process research and development (“IPR&D”) assets and goodwill included the following, among others:

● We obtained and reviewed the ~~business~~Company’s ~~combination~~valuation ~~agreements~~specialist’s ~~outlining~~reports supporting the ~~assets~~annual ~~acquired,~~goodwill ~~liabilities~~impairment ~~assumed,~~analysis. ~~and~~● ~~consideration~~We ~~paid~~evaluated inthe ~~exchange~~significant ~~for~~estimates ~~the~~and ~~transactions.~~inputs ●used Wein ~~reviewed~~ the ~~Company’s~~goodwill ~~Specialist’s~~impairment ~~report~~analysis, ~~related~~including toprojected ~~the~~revenue, ~~valuation~~operating expenses, probability-of-success ~~identifiable~~adjustments, ~~intangible~~income ~~assets~~taxes, ~~and~~net ~~goodwill~~working ~~arising~~capital, ~~from~~capital ~~the~~expenditures, ~~excess~~discount ofrates, ~~the~~and ~~fair~~terminal value ofassumptions. ~~consideration~~● ~~transferred~~We ~~over~~evaluated ~~the~~management’s ~~fair~~conclusion ~~value~~that no impairment of ~~net~~the ~~assets~~Company’s ~~acquired~~goodwill inor ~~business~~indefinite-lived ~~combinations~~intangible ~~during~~IPR&D ~~the~~assets ~~year,~~was indicated by ~~evaluating~~considering the ~~key~~reporting-unit ~~assumptions~~fair ~~used~~values determined in ~~their~~the ~~model,~~third-party ~~including,~~goodwill ~~but~~impairment ~~not~~analysis ~~limited~~and ~~to,~~considering ~~cumulative~~whether ~~probability,~~those ~~discount~~analyses ~~rates,~~supported ~~and~~the ~~future~~carrying ~~projections~~value of the related IPR&D assets. ● We evaluated the ~~reasonableness~~competence, ofcapabilities, ~~the~~and ~~Specialist~~objectivity ~~and~~of ~~their~~management’s ~~report,~~valuation ~~noting~~specialist and concluded they ~~have~~possessed the ~~required~~appropriate ~~skills~~knowledge, ~~knowledge~~skills, and experience, to perform ~~such~~the ~~valuations~~valuation. ~~● Obtained and recalculated client’s deferred tax liability and reviewed for reasonableness.~~

Fruci & Associates II, PLLC – PCAOB ID #05525 ~~We have served as the Company’s auditor since 2023. Spokane, Washington July 29, 2025~~

~~F-2~~We have served as the Company’s auditor since 2023.

~~NORDICUS~~Spokane, ~~PARTNERS CORPORATION~~Washington

July 14, 2026

F-1

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2025			March 31, 2024
	March 31, 2026			March 31, 2025
ASSETS
Current assets:
Cash	$	1920,~~914~~878		$	4919,~~933~~914
Prepaid expenses and other current assets		37512,~~656~~006			—37,656
Total current assets		57532,~~570~~884			4957,~~933~~570
Website		4,840			7,640
In-process research and development		45,506,471			42,708,079
In-process research and development		42,708,079			—
Property, plant, and equipment, net		8,207			—
Other assets		60,089			—
Goodwill		27,161,000			25,490,751
Goodwill		25,490,751			—
Investment in Mag Mile Capital, Inc.		2,250,000			1,925,000
Investment in Mag Mile Capital, Inc.		1,925,000			1,750,000
Other assets		4,784			64,929
Total assets	$	7075,~~246~~463,~~329~~346		$	170,~~807~~246,~~573~~329
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	1,~~062~~111,~~661~~096		$	51,~~019~~062,661
Deferred revenue		—			7,500
Note payable		60,000			—
Related party payable		—			13,886
Total current liabilities		1,171,096			1,062,661
Total current liabilities		1,062,661			26,405
Deferred tax liability		10,054,367			9,318,414
Deferred tax liability		9,318,414			—
Total liabilities		11,225,463			10,381,075
Total liabilities		10,381,075			26,405
Commitments and contingencies		—			—
Stockholders’ equity:
Preferred stock, Series A Junior; $0.001 par value; 500,000 shares authorized; no shares issued and outstanding		—			—
Preferred stock, undesignated; $0.001 par value; 4,500,000 shares authorized; no shares issued and outstanding		—			—
Preferred stock value		—			—
Preferred stock, value		—			—
Common Stock; $0.001 par value; 50,000,000 shares authorized; 17,252,502 and 1,110,226 shares issued and outstanding at March 31, 2025 and March 31, 2024, respectively		17,253			1,110
Common Stock; $0.001 par value; 50,000,000 shares authorized; 19,128,896 and 17,252,502 shares issued and outstanding at March 31, 2026 and March 31, 2025, respectively		19,187			17,253
Treasury stock; 154 shares at cost		(30,328	)		(30,328	)
Treasury stock; 57,796 and 154 shares at cost at March 31, 2026 and March 31, 2025, respectively		(108,722	)		(30,328	)
Additional paid-in capital		~~106~~110,~~047~~842,~~792~~830			45106,~~696~~047,~~761~~792
Accumulated other comprehensive income (loss)		615,385			(2,848	)
Accumulated other comprehensive income		4,314,899			615,385
Accumulated deficit		(4650,~~784~~786,~~848~~534	)		(4346,~~883~~784,~~527~~848	)
Total stockholders’ equity		59,865,254			1,781,168
Total equity attributed to the parent		64,281,660			59,865,254
Total liabilities and stockholders’ equity	$	70,246,329		$	1,807,573
Non-controlling interest		(43,777	)		—
Total stockholders’ equity		64,237,883			59,865,254
Total liabilities and stockholders’ equity	$	75,463,346		$	70,246,329

The accompanying notes are an integral part of these consolidated financial statements.

F-32

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

	For the Years Ended
	March 31,
	2025			2024
	2026			2025
Revenue	$	~~5,000~~—		$	25,~~500~~000
Operating expenses:
Officer compensation		~~662~~615,~~554~~284			~~118~~662,~~477~~554
Professional fees		~~351~~940,~~773~~727			~~137~~351,~~280~~773
Consulting expense		~~248~~317,~~878~~960			—248,878
General and administrative		~~331~~890,~~724~~055			~~54,~~331,724
Research and development		1,~~329~~606,~~436~~972			—1,329,436
Total operating expenses		24,~~924~~370,~~365~~998			~~310~~2,~~088~~924,365
Loss from operations		(24,~~919~~370,~~365~~998	)		(~~307~~2,~~588~~919,365	)
Other (expense) income:
Change in fair value of warrant liability (related party)		(172,715	)		—
Interest expense		(642	)		(200	)
Change in fair value of investment		175,000			—
Change in fair value of warrant liability (related party)		—			(172,715	)
Interest expense		(200	)		—
Change in fair value of investment		325,000			175,000
Other income		—			9,386
Other expense		(164	)		—
Total other (expense) income		2324,~~085~~194			92,~~386~~085
Loss before provision for income taxes		(24,~~917~~046,~~280~~804	)		(~~298~~2,~~202~~917,280	)
Provision for income tax		—			—
Net loss		(24,~~917~~046,~~280~~804	)		(~~298~~2,~~202~~917,280	)
Net loss attributable to noncontrolling interests		(1545,~~959~~118	)		—(15,959	)
Net loss attributable to Nordicus Partners Corporation	$	(24,~~901~~001,~~321~~686	)	$	(~~298~~2,~~202~~901,321	)
Other comprehensive loss:
Other comprehensive income (loss):
Foreign currency translation adjustment	$	~~618~~3,~~233~~700,073		$	(3618,~~513~~233	)
Comprehensive loss	$	(2,283,088	)	$	(301,715	)
Comprehensive income (loss)		(301,613	)		(2,283,088	)
Net loss per share attributable to Nordicus Partners Corporation - basic and diluted	$	(0.32	)	$	(0.29	)
Net comprehensive income attributable to noncontrolling interests		559			—
Weighted average common shares outstanding - basic and diluted		9,205,061			1,034,737
Comprehensive income (loss) attributable to Nordicus Partners Corporation	$	(302,172	)	$	(2,283,088	)
Net loss per share attributable to Nordicus Partners Corporation - basic and diluted	$	(0.22	)	$	(0.32	)
Weighted average common shares outstanding - basic and diluted		18,121,508			9,205,061

The accompanying notes are an integral part of these consolidated financial statements.

F-43

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED MARCH 31, ~~2025~~2026 AND ~~2024~~2025

	Common Stock					Preferred Stock, Series A Junior				Preferred Stock, Undesignated				Additional Paid-in			Accumulated			Treasury			Other Comprehensive			Total Equity Attributed			Non-Controlling			Total Stockholders’
	Shares			Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Stock			Income (Loss)			to Parent			Interest			Equity
Balance at March 31, 2023		829,626		$	830		—	$	—		—	$	—	$	42,254,154			(42,197,663	)		(30,328	)		665			27,658		$	—			27,658
	Common Stock					Preferred Stock, Series A Junior				Preferred Stock, Undesignated				Additional Paid-in			Accumulated			Treasury			Accumulated Other Comprehensive			Total Equity Attributed			Non-Controlling			Total Stockholders’
Shares issued for stock investment		250,000			250		—		—		—		—		1,749,750			—			—			—			1,750,000			—			1,750,000
	Shares			Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Stock			Income (Loss)			to Parent			Interest			Equity
Exercise of warrants		30,600			30		—		—		—		—		305,970			—			—			—			306,000			—			306,000
Deemed dividend for warrant extension		—			—		—		—		—		—		1,387,662			(1,387,662	)		—			—			—			—			—
Cash distribution		—			—		—		—		—		—		(775	)		—			—			—			(775	)		—			(775	)
Foreign currency translation adjustment		—			—		—		—		—		—		—			—			—			(3,513	)		(3,513	)		—			(3,513	)
Net loss		—			—		—		—		—		—		—			(298,202	)		—			—			(298,202	)		—			(298,202	)
Balance at March 31, 2024		1,110,226			1,110		—		—		—		—		45,696,761			(43,883,527	)		(30,328	)		(2,848	)		1,781,168			—			1,781,168
Balance		1,110,226			1,110		—		—		—		—		45,696,761			(43,883,527	)		(30,328	)		(2,848	)		1,781,168			—			1,781,168
Common Stock issued in Orocidin business combination		3,800,000			3,800		—		—		—		—		18,996,200			—			—			—			19,000,000			—			19,000,000
Exercise of warrants		92,776			93		—		—		—		—		895,100			—			—			—			895,193			—			895,193
Cancellation of liability-classified warrants – Related party		—			—		—		—		—		—		167,000			—			—			—			167,000			—			167,000
Common Stock issued for services		30,000			30		—		—		—		—		138,949			—			—			—			138,979			—			138,979
Forgiveness of debt - related party		—			—		—		—		—		—		13,886			—			—			—			13,886			—			13,886
Vesting of restricted stock units - ESG Advisory Group		19,500			20		—		—		—		—		(20	)		—			—			—			—			—			—
Recognition of non-controlling interest in acquisition of Orocidin		—			—		—		—		—		—		—			—			—			—			—			450,000			450,000
Orocidin issuance of common stock in capital raise		—			—		—		—		—		—		183,663			—			—			—			183,663			9,667			193,330
Stock-based compensation		—			—		—		—		—		—		527,625			—			—			—			527,625			—			527,625
Common Stock issued in Bio-Convert business combination, net (See Note 10)		12,000,000			12,000		—		—		—		—		38,985,120			—			—			—			38,997,120			—			38,997,120
Common Stock issued to acquire remaining equity of Orocidin (See Note 10)		200,000			200		—		—		—		—		443,508			—			—			—			443,708			(443,708	)		—
Net loss		—			—		—		—		—		—		—			(2,901,321	)		—			—			(2,901,321	)		(15,959	)		(2,917,280	)
Foreign currency translation adjustment		—			—		—		—		—		—		—			—			—			618,233			618,233			—			618,233
Balance at March 31, 2025		17,252,502		$	17,253		—	$	—		—	$	—	$	106,047,792		$	(46,784,848	)	$	(30,328	)	$	615,385		$	59,865,254		$	—		$	59,865,254
Balance		17,252,502		$	17,253		—	$	—		—	$	—	$	106,047,792		$	(46,784,848	)	$	(30,328	)	$	615,385		$	59,865,254		$	—		$	59,865,254
Stock-based compensation		—			—		—		—		—		—		137,544			—			—			—			137,544			—			137,544
Issuance of restricted common stock		1,850,036			1,850		—		—		—		—		4,351,992			—			—			—			4,353,842			—			4,353,842
Restricted common Stock issued for services		84,000			84		—		—		—		—		304,716			—			—			—			304,800			—			304,800
Equity issued by subsidiary in connection with acquisition of intellectual property		—			—		—		—		—		—		786			—			—			—			786			782			1,568
Repurchase of shares		(57,642	)		—		—		—		—		—		—			—			(78,394	)		—			(78,394	)		—			(78,394	)
Foreign currency translation adjustment		—			—		—		—		—		—		—			—			—			3,699,514			3,699,514			559			3,700,073
Net loss		—			—		—		—		—		—		—			(4,001,686	)		—			—			(4,001,686	)		(45,118	)		(4,046,804	)
Balance at March 31, 2026		19,128,896		$	19,187		—		—		—		—	$	110,842,830		$	(50,786,534	)		(108,722	)	$	4,314,899		$	64,281,660		$	(43,777	)	$	64,237,883
Balance		19,128,896		$	19,187		—		—		—		—	$	110,842,830		$	(50,786,534	)		(108,722	)	$	4,314,899		$	64,281,660		$	(43,777	)	$	64,237,883

The accompanying notes are an integral part of these consolidated financial statements.

F-54

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Years Ended
	March 31,
	2025			2024
	2026			2025
Cash flows from operating activities:
Net loss	$	(24,~~917~~046,~~280~~804	)	$	(~~298~~2,~~202~~917,280	)
Adjustments to reconcile net loss to net cash used in operating activities:
Common Stock issued for services		138,979			—
Shares issued for services		304,800			138,979
Stock-based compensation		~~527~~137,~~625~~544			—527,625
Change in fair value of warrant liability (related party)		~~172,715~~—			—172,715
Change in fair value of investment		(175,000	)		—
Loss on sale of assets		163			—
Amortization of website costs		5,174			—
Change in fair value of investment		(325,000	)		(175,000	)
Non-cash expense of IPR&D		1,559			—
Amortization of website costs		5,198			5,174
Changes in assets and liabilities:
Prepaid expenses and other current assets		(8403,~~784~~553	)		(48,~~245~~784	)
Receivables		—			44,481
Other assets		(1,160	)		(60,089	)
Other assets		(60,089	)		—
Accounts payable and accrued expenses		(81,637	)		1,032,045
Accounts payable and accrued expenses		1,032,045			3,665
Foreign currency remeasurement		84,115			—
Deferred revenue		—			7,500
Net cash used in operating activities		(4,324,775	)		(1,284,615	)
Related party payable		—			(12,127	)
Net cash used in operating activities		(1,284,615	)		(258,928	)
Cash flows from investing activities:
Cash paid for website costs		(2,374	)		—
Proceeds from sale of plant, property, and equipment		7,597			—
Cash acquired in business combinations		150,186			—
Purchase of plant, property, and equipment		(17,755	)		—
Net cash provided by investing activities		147,812			—
Cash paid for website costs		—			(2,374	)
Cash acquired in business combinations		—			150,186
Net cash (used in) provided by investing activities		(10,158	)		147,812
Cash flows from financing activities:
Cash distribution to stockholder		—			(775	)
Cash paid for stock issuance costs in business combinations		—			(2,880	)
Cash paid for stock issuance costs in business combinations		(2,880	)		—
Repurchase of common stock		(78,394	)		—
Proceeds from Orocidin issuance of common stock in capital raise		193,330			—
Proceeds from issuance of common stock		4,353,842			—
Proceeds from exercise of warrants		889,477			306,000
Proceeds from issuance of note payable		60,000			—
Net cash provided by financing activities		1,079,927			305,225
Proceeds from Orocidin issuance of common stock in capital raise		—			193,330
Net change in cash		(56,876	)		46,297
Proceeds from exercise of warrants		—			889,477
Effect of exchange rate on cash		26,857			(3,513	)
Net cash provided by financing activities		4,335,448			1,079,927
Cash at beginning of period		49,933			7,149
Net change in cash		515			(56,876	)
Cash at end of period	$	19,914		$	49,933
Effect of exchange rate on cash		449			26,857
Cash at beginning of period		19,914			49,933
Cash at end of period	$	20,878		$	19,914
Supplemental disclosure of cash flow information:
Income taxes paid	$	—		$	—
Interest paid	$	—		$	—
Supplemental disclosures of non-cash information:
Deemed dividend	$	—		$	1,387,662
NoviThera equity issued for intellectual property	$	1,568		$	—
Common Stock issued for shares of Mag Mile Capital, Inc.	$	—		$	1,750,000
Common Stock issued for the acquisition of Bio-Convert	$	—		$	39,000,000
Common Stock issued for the acquisition of Bio-Convert	$	39,000,000		$	—
Common Stock issued for the acquisition of Orocidin	$	—		$	19,000,000
Common Stock issued for the acquisition of Orocidin	$	19,000,000		$	—
Cancellation of liability-classified warrants – related party	$	—		$	167,000
Cancellation of liability-classified warrants – Related party	$	167,000		$	—
Forgiveness of debt - related party	$	—		$	13,886
Forgiveness of debt - related party	$	13,886		$	—

The accompanying notes are an integral part of these consolidated financial statements.

F-65

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH~~March 31, ~~2025~~2026

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

~~Nordicus~~We ~~Partners~~were ~~Corporation (the “Company,” or “Nordicus” or “we”) was~~ founded in 1993, asreincorporated ain ~~subsidiary~~Delaware ~~of PolyMedica~~in ~~Corporation. On January 31~~2007, ~~2020~~changed ~~(the “Closing Date”), we completed the sale of substantially all of~~ our ~~assets (the~~name ~~“Asset Sale”) for a total purchase price of $7,250,000 pursuant~~ to anAdvanSource ~~Asset~~Biomaterials ~~Purchase~~Corporation Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provided critical characteristics in ~~the~~2008 ~~design~~ and ~~development of medical devices.~~changed ~~Our~~our ~~biomaterials~~name ~~were marketed and sold~~ to ~~medical~~EKIMAS ~~device~~Corporation ~~manufacturers who used our advanced polymers~~ in ~~devices designed for treating a broad range of anatomical sites and disease states~~2020.

AsOn aOctober ~~result~~12, ~~of the Asset Sale~~2021, we ~~ceased~~entered ~~operating~~into as a ~~developer,~~Stock ~~manufacturer,~~Purchase ~~marketer~~Agreement ~~and~~(the ~~seller~~“SPA”) ofwith ~~advanced~~Reddington ~~polymers.~~Partners ~~Subsequent~~LLC, toa California limited ~~the~~liability ~~Closing~~company ~~Date~~(“Reddington”), weproviding ~~became~~for ~~engaged~~Reddington’s inpurchase ~~efforts~~of toa ~~identify~~total ~~either~~of an511,448 ~~(i)~~shares ~~operating~~of ~~company~~our tocommon ~~acquire~~stock, on a post-split basis, or ~~merge~~approximately ~~with~~90% ~~through~~of anour ~~equity-based exchange~~total ~~transaction~~outstanding orcommon ~~(ii)~~stock, ~~investor~~for ~~interested~~total incash ~~purchasing~~consideration aof ~~majority~~$400,000. ~~interest~~Reddington purchased inthe ~~our~~common ~~Common~~stock ~~Stock~~in two tranches, ~~whereby~~which ~~either~~closed ~~transaction~~on ~~would likely~~October ~~result~~12, in2021 a(the ~~change~~“First inClosing”) ~~control~~and March 15, 2022.

OnPursuant ~~March~~to 3the SPA, ~~2020~~the Company effected a 1-for-50 reverse stock split on March 11, we2022 ~~filed~~(the “Reverse Split”). On a ~~Certificate~~post-split basis, ofReddington ~~Amendment~~acquired to42,273 at the ~~Company’s~~First ~~Certificate~~Closing ofand ~~Incorporation.~~an ~~This~~additional ~~amendment~~469,175 ~~was~~shares ~~unanimously approved~~at bythe ~~our~~March ~~Board~~15, of2022 ~~Directors~~second closing, toafter ~~change~~which Reddington owned 511,448 shares of our ~~name~~common ~~from~~stock, ~~AdvanSource~~or ~~Biomaterials~~approximately ~~Corporation~~90% toof ~~EKIMAS~~our ~~Corporation~~total outstanding common stock.

On ~~October~~February 1223, ~~2021~~2023, wethe ~~entered~~Company ~~into~~acquired aNP ~~Stock~~Bioinnovation ~~Purchase~~A/S ~~Agreement~~ (~~the~~formerly ~~“SPA”)~~Nordicus ~~with Reddington~~ Partners ~~LLC,~~A/S aand ~~California~~Managementselskabet ~~limited liability~~af ~~company~~12.08.2020 ~~(“Reddington”~~A/S), a ~~providing~~Danish ~~for~~stock ~~the~~corporation, ~~purchase~~pursuant ofto a ~~total~~contribution ofagreement ~~511,448~~with ~~shares~~NP ofBioinnovation ~~our~~A/S, ~~Common~~GK ~~Stock~~Partners ApS, onHenrik aRouf ~~post-split~~and Life Science ~~basis,~~Power orHouse ~~approximately~~ApS. 90The sellers contributed 100% of ~~our~~the ~~total~~issued ~~shares~~and outstanding capital stock of ~~Common~~NP ~~Stock~~Bioinnovation ~~outstanding,~~A/S ~~for~~to ~~total~~the ~~cash~~Company ~~consideration~~in exchange for an aggregate of ~~$400~~250,000. ~~Reddington~~shares ~~purchased~~ of the ~~Common~~Company’s ~~Stock~~common instock, ~~two~~and ~~tranches~~NP onBioinnovation ~~October~~A/S ~~12,~~became ~~2021~~a ~~and~~wholly ~~March~~owned ~~15,~~subsidiary ~~2022~~of the Company.

Pursuant to the SPA, the Company effectuated a 1-for 50 reverse stock split on March 11, 2022. Accordingly, on a post-split basis, the shares purchased in connection with the First Closing resulted in Reddington owning 42,273 shares of our Common Stock. As set forth in the SPA, Reddington then purchased from us on March 15, 2022, an additional 469,175 shares of our Common Stock, on a post-split basis (the “Second Closing”). After the issuance thereof, Reddington owned 511,448 shares of our Common Stock, or approximately 90% of our total shares of Common Stock outstanding.

On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company.

On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD. On June 1, 2023, the Company acquired a 4.99% interest in Mag Mile Capital, Inc., a commercial real estate mortgage banking firm headquartered in Chicago.

On June 19, 2023, ~~the Company acquired a 4~~Mr.~~99%~~ ~~interest~~Tom inGlaesner ~~Mag~~Larsen ~~Mile~~resigned ~~Capital,~~as ~~Inc. (“Mag Mile Capital”),~~ a ~~full-service~~director ~~commercial real estate mortgage banking firm headquartered in Chicago with offices in the states~~ of New York, Massachusetts, Connecticut, Florida, Texas and Nevada. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the ~~full~~Company ~~capital stack~~ and ~~across all~~Henrik ~~major~~Keller ~~real~~was ~~estate~~appointed ~~asset~~as ~~classes~~his nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneursreplacement.

F-7

On June 9, 2023, Tom Glaesner Larsen resigned from the Company’s Board of Directors, and the remaining board members appointed Henrik Keller as his replacement.

On May 13, 2024, the Company ~~and~~acquired ~~certain~~a ~~shareholders~~95% ofinterest in Orocidin A/S (~~the~~ “Orocidin ~~Sellers~~”), a Danish ~~stock~~preclinical-stage ~~corporation (“Orocidin”),~~biotechnology ~~entered~~company ~~into~~advancing anext-generation ~~Stock~~periodontitis ~~Purchase and Sale Agreement (the “Agreement”)~~therapies, ~~under~~in ~~which the Orocidin Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock. In~~ exchange, ~~the~~for ~~Company issued~~ 3,800,000 restricted shares of ~~its Common Stock to~~ the ~~Orocidin~~Company’s ~~Sellers. The~~common ~~transaction was consummated on May 13, 2024~~stock. ~~Orocidin A/S, is a preclinical-stage biotechnology company which is advancing the next generation of periodontitis therapies.~~

On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement.

On November 8, 2024, the Company effected a 1:-for-10 reverse stock split of its ~~Common~~issued ~~Stock~~and outstanding common stock, rounding up for fractional shares. The reverse stock split had no effect on the Company’s authorized shares of common stock or preferred stock, and the par value of each class remained $0.001. All common stock share, option, warrant and per-share amounts, except authorized but unissued shares, have been retroactively adjusted in these consolidated financial statements and related disclosures.

~~On November 11, 2024, the Company announced that it entered into an agreement with Bio~~F-Convert A/S (“Bio-Convert”) to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 restricted shares of the Company’s Common Stock. Bio-Convert is a Denmark-based preclinical-stage biotechnology company aiming to revolutionize the treatment of oral leukoplakia by minimizing or removing oral leukoplakia lesions in order to further reduce the risk of such lesions resulting in the development of oral cancer in patients.6

On November 1211, 2024, the Company announced that it had entered into an agreement ~~with Orocidin A/S~~ to acquire ~~the~~100% ~~remaining~~of ~~29,663~~the outstanding shares, ~~or approximately 5%,~~ of ~~Orocidin~~ Bio-Convert A/S. ~~In exchange~~(“Bio-Convert”), ~~the~~a ~~Company~~Denmark-based ~~issued~~preclinical-stage ~~200,000~~biotechnology ~~shares~~company ofdeveloping ~~restricted~~treatments ~~Common~~for ~~Stock~~oral ~~to the selling shareholders of Orocidin.~~leukoplakia, ~~Upon~~in ~~closing~~exchange offor ~~the acquisition~~12,000,000 ~~Orocidin~~restricted ~~A/S~~shares ~~became a 100% wholly owned subsidiary~~ of the Company’s common stock.

On November 12, 2024, the Company acquired the remaining 29,663 outstanding shares, or approximately 5%, of Orocidin A/S in exchange for 200,000 restricted shares of the Company’s common stock, after which Orocidin A/S became a wholly owned subsidiary of the Company.

In October 2025, the Company formed NoviThera ApS (“NoviThera”) to research and develop a monoclonal antibody (MaB) therapy for the treatment of psoriasis. The invention and initial development were made and performed by Alteral Therapeutics (“Alteral”), a Denmark-domiciled related party of the Company. Mr. Allan Wehnert, who controls Alteral, was appointed Chief Executive Officer of NoviThera. In exchange for contributing intellectual property to NoviThera, Alteral received a 49.9% ownership interest in NoviThera, and the Company retained a 50.1% ownership interest.

Description of Business

~~Since~~Nordicus ~~the~~Partners ~~current~~Corporation ~~leadership assumed control of~~ (“Nordicus,” or the “Company”) ~~has~~is ~~evolved into~~ a ~~business~~U.S. ~~accelerator~~publicly ~~and~~listed ~~holding~~biotech company ~~dedicated~~specializing in todeveloping ~~helping~~breakthrough ~~Nordic~~therapeutics ~~life~~in ~~sciences~~diseases ~~companies~~with ~~succeed~~unmet inmedical ~~the American market~~needs. ByNordicus ~~combining~~focuses ~~Nordic~~on ~~innovation~~acquiring ~~with~~and ~~U.S.~~developing ~~operational~~drugs ~~expertise,~~from innovative ~~the~~biotech ~~Company~~companies ~~endeavors~~in tothe ~~create~~Nordics, a ~~distinct~~region ~~advantage~~known infor ~~identifying,~~its ~~scaling~~brilliant scientists, ~~and~~exceptional ~~exiting~~life ~~high-potential~~science ~~companies~~ecosystem ~~in fast-growing markets~~and ~~with~~drug ~~unmet~~discoveries ~~medical~~and ~~needs~~developments. Nordicus’ ~~mission~~ is dedicated to ~~back~~developing ~~high-growth~~breakthrough ~~ventures~~therapeutics ~~and~~in ~~transformative~~diseases ~~innovations~~with inunmet ~~the~~medical ~~life sciences~~needs ~~sector.~~– ~~Nordicus’~~starting ~~portfolio diversification strategy aims to positions it as a stable and resilient company, mitigating risk~~ with ~~significant~~ ~~upside~~oral ~~potential~~disorders.

~~Nordicus’~~Its ~~current~~scientific ~~life~~foundation ~~sciences~~targets ~~portfolio~~inflammation ~~consists~~and ofimmune ~~two~~modulation. ~~preclinical~~In ~~biotechnology~~2024, ~~companies~~Nordicus inacquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, ~~led~~a byDanish ~~the~~preclinical-stage ~~accomplished~~biotech ~~pharmacologist,~~company ~~Allan~~dedicated ~~Wehnert,~~to ~~who~~revolutionizing ~~serves~~the astreatment ~~CEO~~ of ~~both~~oral ~~companies~~leukoplakia.

~~Orocidin~~Nordicus’ ~~A/S~~portfolio isdiversification ~~developing~~strategy apositions ~~proprietary~~it ~~first-of-its-kind~~as ~~medical treatment for aggressive periodontitis. Most recently, Orocidin A/S successfully completed~~ a ~~14-day~~stable ~~toxicology study in hamsters~~ and aresilient ~~test~~company, ofmitigating ~~effectiveness~~risk inwith asignificant ~~Beagle~~upside ~~Dog Study, respectively~~potential.

~~Bio~~F-Convert A/S is focused on a treatment against oral leukoplakia (OLK) – an oral potentially malignant disorder – by developing a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia. Most recently, Bio-Convert A/S received positive and constructive scientific advice from the Danish Medicines Agency (DKMA) regarding its lead candidate, QR-02, as a treatment for oral leukoplakia.7

~~F-8~~Our Approach and Value Creation Process

Nordicus employs a 4-step value creation process:

–

Scout and Accelerate: Nordicus targets high-impact potential companies, providing capital, resources and expertise to drive critical milestones such as patent filings and clinical trials.

–

Acquire and Exit: Nordicus acquires controlling stakes to maximize value creation and exit at premium multiples.

Nordicus aims to take all portfolio companies’ drug developments through Phase I. Upon completion of Phase I, the following options will be considered:

Sale or merger of the portfolio company.

Further development through the next clinical phases.

Strategic partnership with a large pharmaceutical company that will invest in Nordicus for further drug development.

Stand-alone Initial Public Offering (IPO).

Nordicus’ current life sciences portfolio consists of two promising preclinical biotechnology companies in Orocidin A/S and Bio-Convert A/S led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of both companies. In October 2025 formed a third subsidiary, NoviThera, also to be led by Alan Wehnert.

The companies’ innovative breakthroughs are further strengthened by their oral formulations ensuring prolonged adhesion for 12-24 hours and controlled release of the active ingredient, enhancing drug efficacy and patients’ outcomes – a major advancement over normal gels and creams.

NoviThera is developing a drug for the treatment of psoriasis, an Immune-medicated inflammatory disease that causes keratinocyte hyperproliferation and inflammation.

Orocidin A/S

Orocidin A/S has successfully completed a 14-day toxicology study in hamsters and two tests of effectiveness in a Beagle Dog Study and a Wistar Rat Study.

In the 14-days toxicology study, all animals exhibited high tolerance to the drug, with no adverse reactions and irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues. The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study.

F-8

The Beagle Dog Study is the first study that shows Orocidin A/S drug, QR-01, having a direct effect on periodontitis diagnosed beagle dogs. The 13-day small efficacy study was conducted on beagle dogs with clinically confirmed periodontitis. The dogs demonstrated consistent improvements across key clinical endpoints, including the Gingival Index, the Plaque Index and overall periodontal disease.

Moreover, QR-01 was well tolerated, with no adverse side effects reported throughout the treatment period. This represents a significant milestone for Orocidin’s lead product, QR-01, and strengthens Nordicus’ and Orocidin’s confidence as Orocidin prepare for the upcoming human pilot efficacy study.

In the second efficacy study, rats with induced periodontitis treated with QR-01 demonstrated improvements in Probing Depth (PD-mm), Gingival Index (GI), Bleeding on Probing (BOP) and Plaque Levels (PL). More importantly, lower bone loss was demonstrated in treated rats compared to non-treated rats measured by micro-CT scanning. Until now, this has not been demonstrated.

In summary, Orocidin has now demonstrated efficacy in treating periodontitis in two different animals using 2 methods. The first Phase IIa clinical trials study in patients is now anticipated to start in the first half of 2027 at the University of Copenhagen in Denmark.

Bio-Convert

Bio-Convert’s QR-02 compound targets Oral Leukoplakia (OLK), which are potentially pre-cancerous lesions in the mouth, with up to a 30% conversion rate to oral cancer. No approved medical treatment exists for OLK, with surgery the only true alternative.

The company’s proprietary oral gel QR-02 has several unique advantages, including antitumor & antiviral effects, reducing the risk of dysplasia and enabling more precise and efficient treatment, compared to any methods used today.

Bio-Convert obtained a toxicity waiver from the Danish Medicine Agency’s (DKMA) for QR-02 and is currently finalizing its GMP (Good Manufacturing Practice) product to be completed by December 2026 in Germany. Bio-Convert anticipates moving into Phase IIa clinical trials in Europe beginning the first half of 2027.

NoviThera

NoviThera recently completed a study in mice, and with such study demonstrated biological proof of concept.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).

F-9

Reverse Stock Split

On November 8, 2024, the Company effectuated a 1-for-10 reverse stock split of its issued and outstanding Common Stock, rounding up to account for any fractional shares. The ~~Reverse~~reverse ~~Stock~~stock ~~Split~~split had no effect on the Company’s authorized shares of Common Stock or Preferred Stock and the par value of both remained unchanged at $0.001. All Common Stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these condensed consolidated financial statements and related disclosures.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill, and the fair value of assets acquired and liabilities assumed in business combinations~~, and the fair value of its warrants to purchase common stock~~.

Concentration of Credit Risk

WeThe ~~maintain~~Company ~~our~~maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. WeThe Company also ~~maintain~~maintains cash in foreign bank accounts that are not federally insured. WeThe Company continually ~~monitor~~monitors ~~our~~its banking relationships and consequently ~~have~~has not experienced any losses in ~~our~~its accounts. WeThe ~~believe~~Company webelieves ~~are~~it is not exposed to any significant credit risk on cash.

Cash and Cash Equivalents

Cash amounts include cash on hand and cash on deposit with banks. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of March 31, ~~2025~~2026 and March 31, ~~2024~~2025.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, —NP ~~Bioinnovation~~ Bioinnovation A/S, Orocidin ~~A/S~~, and Bio-Convert—and ~~A/S~~its majority-owned subsidiary, NoviThera. All significant intercompany transactions have been eliminated in consolidation.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s Chief operating decision-maker (“CODM”), the Company’s chief executive officer, view the Company’s operations and manages its business as a single operating segment. See Note 1314 for more information.

Translation Adjustment

The reporting currency of the Company is U.S. Dollars. The accounts of the Company’s subsidiaries are maintained in Danish krone. ~~According~~In toaccordance with, Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Matters, all assets and liabilities ~~were~~ are translated at the current exchange rate at respective balance sheets dates, stockholders’ equity transactions are translated at at the historical rates and statement of operations accounts are translated at the average exchange rate for the period. The resulting ~~translation~~ translation adjustments are reported in other comprehensive income (loss) in accordance with ASC Topic 220, Reporting Comprehensive Income (“ASC 220”) in the condensed consolidated statements of operations and in accumulated other comprehensive income (loss) as a component of stockholders’ equity.

~~F-9~~Comprehensive Income (Loss)

Comprehensive ~~Loss~~income (loss) is comprised of net loss and all changes to the consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income (loss) is inclusive of net loss and foreign currency translation adjustments.

Comprehensive loss is comprised of net loss and all changes to the consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive loss is inclusive of net loss and foreign currency translation adjustments.

Research and Development Costs

Research and development costs consists primarily of costs associated with Orocidin, ~~and~~ Bio-Convert, and NoviThera’s ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future ~~research~~ research and development activities are expensed when the activity has been performed or when the goods have been received.

F-10

Stock-based Compensation

The Company accounts for stock-based compensation using the provisions of ASC Topic 718, Stock Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures ~~of grants~~ as they occur. Compensation cost for service awards is recognized using the straight-line method over the vesting period. Compensation cost for performance awards is recognized when the vesting condition becomes probable of occurring. Stock-based compensation is included in officer compensation, general and administrative, research and development, and consulting expense in the condensed consolidated statements of operations and comprehensive loss.

Fair Value of Financial Instruments

The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1:	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2:	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3:	Pricing inputs that are generally unobservable inputs and not corroborated by market data.

The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments.

Prior to its cancellation, the Company’s liability-classified warrant issued on December 30, 2024 to GK Partners was considered to be a Level 3 financial instrument measured at fair value at issuance. Subsequent changes in fair value were recognized each reporting period within the consolidated statement of operations and comprehensive loss.

Distinguishing Liabilities from Equity

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in the FASB ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815, Derivatives and Hedging. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, and whether the warrants meet all of the requirements for equity classification under ASC Topic 815, including whether the warrants are indexed to the Company’s Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and on the date of issuance and for liability-classified awards, remeasured to fair value at each balance sheet date thereafter.

FFor issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-10in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized in change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive income (loss).

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized in change in fair value of warrant liabilities in the consolidated statements of operations and comprehensive loss.

Net Loss per Share

Net loss per share is computed pursuant to ASC Topic 260, Earnings Per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares of Common Stock and potentially outstanding shares of Common Stock during the period. As of March 31, ~~2025~~2026, there were ~~900~~1,000,000 potentially dilutive shares of Common Stock from 75,000 ~~equity~~ equity-classified warrants and ~~825~~925,000 stock options. As of March 31, ~~2024~~2025, there were ~~632,~~900,000 potentially dilutive shares of ~~Common~~ ~~Stock~~common stock from equity -classified warrants. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

F-11

Business Combinations

The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the ~~consolidated~~condensed ~~financial~~consolidated financial statements from the acquisition date.

Purchase Accounting Measurement Period Adjustments

From time to time, the Company makes acquisitions accounted for as business combinations under ASC 805. Certain asset and liability values are initially recorded as provisional and may be adjusted during the measurement period as new information becomes available. Finalized valuations result in retrospective adjustments to reflect facts and circumstances that existed at the acquisition date.

During the year ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration for Bio-Convert, inclusive of non-cash consideration paid by the Company and in-process research and development. The measurement period adjustment resulted in (i) a $26,475,819 increase in in-process research and development recorded and (ii) recognition of a $5,868,647 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill.

During the year ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration, inclusive of non-cash consideration paid by the Company and the fair value of non-controlling interest, and in-process research and development. The measurement period adjustment resulted in (i) a $450,000 net increase in total consideration paid, (ii) a $15,457,444 increase in in-process research and development recorded, and (iii) recognition of a $3,449,767 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill.

Goodwill

The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company’s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of the Company’s reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, operating results, probability-adjusted cash flows, discount rates and other market participant assumptions. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.

F-1112

The Company assesses goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. The Company did not record an impairment charge during the years ended March 31, ~~2025~~2026 and ~~2024~~2025.

Indefinite-lived Intangible Assets

The Company accounts for its indefinite-lived intangible assets in accordance with ASC Topic 350, Intangibles - Goodwill and ~~Other~~ Other (“ASC 350”). Indefinite-lived intangible assets are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, the Company tests its indefinite-lived intangible assets, which consist of certain in-process research and development (IPR&D) assets acquired via the Company’s business combinations with Orocidin ~~A/S~~ and Bio-Convert ~~A/S~~ detailed in Note 10, for impairment by comparing their fair values to their carrying values. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, probability-adjusted development and commercialization assumptions, discount rates and other market participant assumptions. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values. The Company did not record an impairment charge during the years ended March 31, ~~2025~~2026 and ~~2024~~2025.

Revenue Recognition

The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company determines revenue recognition through the following steps:

	●	Identification of a contract with a customer;
	●	Identification of the performance obligations in the contract;
	●	Determination of the transaction price;
	●	Allocation of the transaction price to the performance obligations in the contract; and
	●	Recognition of revenue when or as the performance obligations are satisfied.

InThe ~~January 2024, the~~ Company signed an agreement with Orocidin for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Orocidin became a subsidiary in the quarter ended June 30, 2024, no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction.

InThe ~~June 2024, the~~ Company signed an agreement with Bio-Convert for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Bio-Convert became a subsidiary in the quarter ended December 31, 2024, no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction.

Non-controlling Interests

In accordance with ASC Topic 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.

Following the acquisition of 95% of Orocidin ~~A/S~~ in May 2024, the Company determined that Orocidin ~~A/S~~ was a VIE, and that the Company was the ~~primary~~ primary beneficiary. While the Company owned 95% of Orocidin ~~A/S~~’s equity interests, the remaining equity interests in Orocidin ~~A/S~~ were owned by unrelated third parties, and the agreement with these third parties provided the Company with greater voting rights. Accordingly, the Company consolidated its interest in Orocidin ~~A/S~~ under the VIE rules and reflected the third parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial ~~fair~~ fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net ~~income~~ income or loss or equity contributions and distributions. These non-controlling interests ~~are~~were not redeemable by the equity holders and ~~are~~ were presented as part of permanent equity. Income and losses ~~are~~were allocated to the non-controlling interest holders based on its economic ownership percentage. Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity.

F-1213

In November 2024, the Company acquired the remaining 5% interest in Orocidin ~~A/S~~. As a result, Orocdin ~~A/S~~ became a wholly owned subsidiary and was is no longer considered a VIE. The noncontrolling interest in Orocidin was derecognized from the Company’s ~~consolidated~~condensed ~~financial~~consolidated financial statements at the time of the acquisition of the remaining 5% interest. ~~Refer to Note 10 (“Business Combinations”) for more information regarding non-controlling interest recognized and derecognized related to the Orocidin A/S transactions.~~

Following the creation of NoviThera in October 2025 and the issuance of equity in NoviThera to Alteral, the Company determined that NoviThera was a VIE, and that the Company was the primary beneficiary. While the Company owned 50.1% of NoviThera’s equity interests, the remaining equity interests in NoviThera are owned by a related party, and the agreement with the related party provided the Company with greater voting rights based on each party’s equity interest. Accordingly, the Company consolidated its interest in NoviThera under the VIE rules and reflected the related parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. Income and losses were allocated to the non-controlling interest holders based on its economic ownership percentage.

Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity.

The consolidated balance sheet as of March 31, 2026 includes balances for NoviThera of $4,616 of cash,$5,707 for prepaid expenses and other current assets, $12,556 for other assets, and $91,422 accounts payable and accrued expenses.

Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company’s products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.

~~New~~Income ~~accounting pronouncements adopted~~Taxes

InThe ~~November~~following ~~2023,~~table ~~the~~summarizes ~~Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) 2023-07, with~~ the ~~goal~~deferred ofincome ~~enhancing~~tax ~~segment~~activity disclosures under Topic 280 - Segment Reporting, which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. This Update is applicable for all public entities. The amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted the ~~provisions~~year ofended ~~ASU 2023-07 as of~~ March 31, ~~2025 on a retrospective basis. The adoption did not have a material impact on the consolidated financial statements, refer to Note 13, Segment Information.~~2026:

	Orocidin		Bio-Convert		Total
Balance as of March 31, 2025	$	3,449,767	$	5,868,647	$	9,318,414
Foreign currency translation adjustment		225,776		510,177		735,953
Balance as of March 31, 2026	$	3,675,543	$	6,378,824	$	10,054,367

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09, effective March 31, 2026, in these consolidated financial statements. ASU 2023-09 only impacted the disclosures and did not otherwise impact the consolidated financial statements. See Note 12, Income Taxes, for disclosures related to the adoption of ASU 2023-09.

F-14

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. Early adoption of the amendments is permitted for annual financial statements that have not yet been issued. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. This ASU was further clarified by ASU 2025-01, Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures, Disaggregation of Income Statement Expenses, which was issued in December 2024. The new standards require disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standards will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of these accounting standard updates on its financial statements.

The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

F-13

NOTE 3 - GOING CONCERN

The Company’s consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has recognized nominal revenue and has incurred losses since inception resulting in an accumulated deficit of $4650,~~784~~786,~~848~~534 and held cash of $20,878 as of March 31, ~~2025~~2026. As a result, the Company’s current funds will not be sufficient to meet ~~our~~its needs for more than twelve months from the date of issuance of these condensed consolidated financial statements. Accordingly, there is substantial doubt about the ability to continue as a going concern.

The ability to continue as a going concern is dependent upon the Company’s recent acquisitions, its generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and ~~the~~through private ~~placement~~placements of Common Stock. In April 2026, the Company issued to a certain private investor for a total of 45,000 restricted shares of its common stock, par value $0.001 per share. The ~~consolidated~~price per share was $2.75 for gross proceeds of $0.1 million. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 4 - INVESTMENTS

On June 20, 2023, the Company and GK Partners ApS entered into a Stock Purchase and Sale Agreement, under which GK Partners ApS sold to the Company 5,000,000 restricted shares of common stock of Mag Mile Capital~~, Inc~~. ~~(“Mag Mile”).~~ The shares were restricted in that they were subject to a registration statement being filed on Form S-1 by Mag Mile on September 6, 2023. The Form S-1 became effective on July 5, 2024, removing the restriction on the shares. In exchange, the Company issued 250,000 restricted shares of its Common Stock to GK Partners ApS. The shares were valued at $1,750,000, at a price of $7.00 per share, the closing stock price for the Company’s Common stock on the last business day before the agreement.

The Company ~~previously~~accounts ~~accounted~~ for its investment under the guidance of ASC Topic 321, Investments – Equity Securities, which provides guidance for equity interests that meet the definition of an equity security. Equity interests with readily determinable fair values are carried at fair value with changes in value recorded in earnings. Investments without readily determinable fair values are accounted for using the measurement alternative which is at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

There is an active market for the shares of Mag Mile as of March 31, ~~2025~~2026. Therefore, the investment had an observable change in the value of Mag Mile’s shares that can be used to adjust the value of the Company’s investment in those shares. During the year ended March 31, ~~2025~~2026, the Company observed price changes to the ~~cost~~trading ~~basis~~price per share of Mag Mile’s common stock and recorded an increase of $325,000 in the Company’s investment. inPrior ~~Mag~~to ~~Mile~~December 31, ~~resulting~~2024, inthere was no active market for the shares of Mag Mile and the Company carried the investment at cost until such time that there was an ~~increase~~indicator of ~~$175,000~~impairment or an observable change in the value of Mag Mile’s shares that could be used to adjust the value of the Company’s investment in those shares. Prior to there being an active market for the shares of Mag Mile, no impairment of the carrying value of the investment was recorded.

F-15

NOTE 5 - RELATED PARTY TRANSACTIONS

Mr. Tom Glasner Larsen is the spouse of Mrs. Glaesner, CEO of GK Partners, and was a member of our board of directors from February 23, 2023 until his voluntary retirement on June 9, 2023. He was a beneficial owner of a controlling interest in NP Bioinnovation A/S (formerly Managementselskabet af 12.08.2020 A/S) until its acquisition by the Company on February 23, 2023. He was also a beneficial owner of a controlling interest in Orocidin ~~A/S~~ until its acquisition by the Company on May 13, 2024, and a beneficial owner of a controlling interest in Bio-Convert ~~A/S~~ until its acquisition by the Company on November 11, 2024.

Effective April 1, 2022, we issued to GK Partners, for financial services, a warrant (the “2022 GK Warrant”) to purchase up to 600,000 shares of our Common Stock at an exercise price of $10.00 per share, and which had an expiration date of December 31, 2023. The Company determined that the 2022 GK Warrant iswas not precluded from equity classification and was therefore recorded within additional paid-in capital on the Company’s consolidated balance sheets at its issuance date fair value. On December 22, 2023, the expiration date of the warrant, covering 570,500 remaining unexercised warrant shares, was extended to December 31, 2024 . ~~During the year ended March 31, 2024, GK Partners exercised a portion of its warrant for a total of 30,600 shares. The exercise price was $10.00 per share for total proceeds of $306,000.~~ For the year ended March 31, 2025, GK Partners exercised a portion of its warrant for 57,400 shares. The exercise price was $10.00 per share for total proceeds of $576,000. On December 31, 2024 the 2022 GK Warrant expired.

~~F-14~~Effective December 30, 2024, warrants were issued to GK Partners (the “2024 GK Warrant”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price equal to the greater of $8.91 and the daily volume weighted average price of the Common Stock for the ten trading days immediately preceding the date of exercise. The 2024 GK Warrant was scheduled to expire on December 31, 2025. The Company determined that the 2024 GK Warrant was precluded from being classified within equity and was liability classified under ASC Topic 815, Derivatives and Hedging. During the year ended March 31, 2025, GK Partners exercised a portion of its 2024 GK Warrant for a total of 35,176 shares. The exercise price ranged from $8.91 to $8.95 per share for total proceeds of $313,455. On March 31, 2025, the 2024 GK Warrant was terminated. Immediately prior to the termination, the fair value of the 2024 GK Warrant was $167,000, which was reclassified to additional paid in capital due to the related party relationship with GK Partners.

As detailed in Note 4, on June 20, 2023, the Company and GK Partners entered into a Stock Purchase and Sale Agreement whereby the Company acquired equity interests in Mag Mile.

~~Mr.~~During ~~Bennett~~the ~~Yankowitz,~~year ~~our~~ended ~~chief~~March ~~financial~~31, ~~officer and director~~2026, ~~was~~GK ~~affiliated~~Partners ~~with~~purchased ~~legal~~49,000 ~~counsel~~shares ~~who~~of ~~provided us with general legal services (~~the ~~“Affiliate”).~~Company’s Wecommon ~~recorded~~stock ~~legal~~at ~~fees~~a toprice ~~the Affiliate~~ of $~~79,463~~5.00 ~~and~~per ~~$17,022~~ share for ~~the~~gross ~~years~~proceeds ~~ended March 2025 and 2024, respectively. As~~ of ~~March 31~~$245, ~~2025 and March 31, 2024, we had no outstanding payable due to the Affiliate for either period~~000.

~~Our~~In ~~employment~~July ~~agreement with Henrik Rouf~~2025, ~~our~~NP ~~chief~~Bioinnovation ~~executive~~A/S ~~officer,~~entered ~~provided~~into ~~for~~ a ~~base salary of $72,000 per year, commencing April 1, 2023, and had a~~ short-term oflease ~~1one year. On April 8, 2024 the~~ agreement ~~was~~with ~~amended~~GK ~~to increase Mr~~Partners. ~~Rouf’s~~NP ~~annual~~Bioinnovation ~~salary~~A/S toincurred $~~120~~37,~~000 and~~776 ~~to extend the term to April~~of 1,expense ~~2025.~~related ~~On July 1, 2025 the agreement was amended~~ to ~~increase Mr. Rouf’s annual salary to $360,000 and to extend~~ the ~~term~~lease ~~to July 1, 2026~~agreement.

For the year ended March 31, 2026, GK Partners provided services to the Company’s subsidiaries totaling approximately $126,658.

Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $3,665 and $79,463 for the years ended March 31, 2026 and 2025, respectively. As of March 31, 2026 and March 31, 2025, we had no outstanding payables due to the Affiliate for either period.

Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $120,000 and to extend the term to April 1, 2025. On July 1, 2025 the agreement was amended to increase Mr. Rouf’s annual salary to $360,000 and to extend the term to July 1, 2026.

Our consulting agreement with Bennett Yankowitz, our chief financial officer and a member of our board of directors, provided for a base salary of $36,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Yankowitz’s annual salary to $60,000 and to extend the term to April 1, 2025. On July 1, 2025 the agreement was amended to increase Mr. Yankowitz’s annual salary to $120,000 and to extend the term to July 1, 2026.

F-16

During the year ended March 31, 2025, a related party forgave their payable of $13,886. The amount has been credited to additional paid in capital.

Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of the Company, and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors. Mr. Hill-Madsen will continue as CEO of NP Bioinnovation A/S, of which the Company acquired 100% of the outstanding shares in exchange for shares of the Company on February 23, 2023.

On June 3, 2024, the Company’s Board of Directors approved a compensation plan under which the Chairman of the Board of Directors will receive compensation of $20,000 per annum, and each other Director will receive compensation of $10,000 per annum, in consideration of their serving on the Corporation’s Board of Directors, payable in equal installments semiannually in arrears, commencing December 31, 2024, without proration for partial terms. As of March 31, 2026, $15,000 is included in accounts payable and accrued expenses.

On October 1, 2025, the Company entered into a consulting agreement with Darlington Group, LLC (“Darlington Group”), which is controlled by Andrew Ritter, a member of the Company’s board of directors. Darlington Group will provide consulting services concerning strategic guidance on U.S. capital markets and drug development; market access and network development; partnerships, industry intelligence and strategic planning; and operational support. The agreement is terminable by either party on 30 days’ advance notice. For these services, Darlington Group will be paid $10,000 in advance per quarter on each October 1, January 1, April 1 and July 1 during the term of the agreement, commencing October 1, 2025.

In October 2025, the Company, through its subsidiary NoviThera, purchased intellectual property from Alteral in exchange for 49.9% equity stake in NoviThera, to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis. Mr. Allan Wehnert, who controls Alteral Therapeutics, was appointed CEO of NoviThera. As a result of the purchase, the Company retained a controlling 50.1% ownership interest in NoviThera. The Company expensed the acquired in-process research and development of $527,625 at the acquisition date because the assets had no alternative future use.

NOTE 6 - FAIR VALUE MEASUREMENTS

The following tables provide information related to the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, ~~2025~~2026 and ~~2024~~March 31, 2025:

March 31, 2026

Level 1

Level 2

Level 3

Total

March 31, 2025

Level 1

Level 2

Level 3

Total

Assets:

Investment in Mag Mile Capital, Inc.

12,~~925~~250,000

—

12,~~925~~250,000

Assets

12,~~925~~250,000

—

12,~~925~~250,000

F-15


	March 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Investment in Mag Mile Capital, Inc.	$	1,925,000	$	—	$	—	$	1,925,000
Assets	$	1,925,000	$	—	$	—	$	1,925,000

	Level 1		Level 2		Level 3		Total
	March 31, 2024
	Level 1		Level 2		Level 3		Total
Assets:
Investment in Mag Mile Capital, Inc.	$	1,750,000	$	—	$	—	$	1,750,000
Assets	$	1,750,000	$	—	$	—	$	1,750,000

The fair value of the 2024 GK warrant liability (related party), issued during the year ended March 31, 2025, was classified as Level 3 fair value measurement. This amount is not included in the table above, as the warrants were terminated on the balance sheet date. The fair value was estimated using a Monte Carlo Simulation model. The use of significant unobservable inputs could result in those inputs being different at the reporting date and which could result in a significantly higher or lower fair value measurement at the reporting date. The following table presents the quantitative information regarding Level 3 fair value measurement of the warrant liability (related party) upon reclassification of the warrants from equity-classified to liability-classified and as of March 31, 2025, immediately before the warrants were cancelled:

SCHEDULE OF FAIR VALUE MEASUREMENT OF WARRANT LIABILITY

	March 31, 2025			December 31, 2024
Risk-free interest rate		4.05	%		4.08	%
Expected term (years)		0.75			1.00
Exercise price	$	8.91		$	8.91
Annual volatility		198	%		155	%
Stock price on valuation date	$	4.75		$	9.00

The following table summarizes the activity for the Company’s Level 3 instruments measured at fair value on a recurring basis:

SCHEDULE OF LEVEL 3 INSTRUMENTS MEASURED AT FAIR VALUE RECURRING BASIS

	Warrant Liability (Related Party)
Balance as of March 31, 2024	$	—
Reclassification of warrants from equity classified to liability (related party)		280,000
Change in fair value of warrant liability (related party)		(107,285	)
Warrant exercises		(5,715	)
Cancellation of liability-classified warrants (related party)		(167,000	)
Balance as of March, 31, 2025	$	—

There were no transfers between Level 1 and Level 2, nor into and out of Level 3, during the periods presented.

NOTE 7 - PREFERRED STOCK

Preferred Stock

We have authorized 5,000,000 shares, $0.001 par value, preferred stock (the “Preferred Stock”) of which 500,000 shares have been issued and redeemed, and therefore are not considered outstanding. In addition, 500,000 shares of Preferred Stock have been designated as Series A Junior Participating Preferred Stock (the “Junior Preferred Stock”) with the designations and the powers, preferences, rights, qualifications, limitations and restrictions specified in the Certificate of Designation of the Junior Preferred Stock filed with the Delaware Department of State on January 28, 2008. Such number of shares may be increased or decreased by resolution of the Board of Directors, provided that no decrease shall reduce the number of shares of Junior Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Company that are convertible into Junior Preferred Stock. Each share of Junior Preferred Stock shall entitle the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders. The holders of shares of Junior Preferred Stock, in preference to the holders of the Company’s Common Stock and of any other junior stock, shall be entitled to receive, when and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash. Upon the Company’s liquidation, dissolution or winding up, no distribution shall be made to the holders of shares of stock ranking junior to the Junior Preferred Stock unless, prior thereto, the holders of shares of Junior Preferred Stock shall have received $100 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon. The Junior Preferred Stock shall rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of Preferred Stock. As of March 31, ~~2025~~2026 and March 31, ~~2024~~2025, there are no shares of Junior Preferred Stock or undesignated Preferred Stock issued and outstanding.

F-1617

NOTE 8 - COMMON STOCK TRANSACTIONS

The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share (the “Common Stock”). Holders of the Company’s Common Stock are entitled to one vote for each share.

During the year ended March 31, ~~2025~~2026, GKthe ~~Partners~~Company ~~exercised~~issued ~~a portion of its warrants for 92~~1,~~776~~850,036 shares of restricted Common Stock to private investors. The ~~exercise~~purchase price ~~was~~ranged from $101.90-5.00 per share, resulting in total net proceeds of $~~895,193~~4.4 million.

~~During~~In August 2025, the ~~year~~Company’s ~~ended~~Board ~~March~~of ~~31,~~Directors ~~2025,~~authorized a share repurchase program which permits the Company ~~issued~~to 30repurchase up to an aggregate of 200,000 shares of the Company’s Common Stock ~~for~~from ~~services~~existing shareholders only, solely in privately negotiated transactions, at a purchase price per share not greater than the then-current market price as determined based on the last reported sale price of the Company’s Common Stock on the Company’s principal trading market. The ~~value~~Company ofis not obligated to repurchase any shares and may suspend or terminate the program at any time. Repurchased shares ~~issued~~may ~~resulted~~be held as treasury stock or retired, as determined by the Company. The repurchase program will remain in aeffect ~~total~~until ~~non-cash~~the ~~expense~~earliest of ~~$138~~(i) the repurchase of 200,~~979~~000 shares, (ii) 12 months from the date the program was authorized, or (iii) revocation by further Board action.

On ~~May~~October 131, ~~2024~~2025, the Company ~~and~~repurchased ~~certain~~57,642 ~~shareholders~~shares of ~~Orocidin~~Common ~~A/S,~~Stock ~~entered~~from ~~into~~an aexisting ~~Stock~~shareholder ~~Purchase~~for ~~and~~$1.36 ~~Sale~~per ~~Agreement,~~share. ~~under~~The ~~which~~repurchase ~~the~~was ~~Company~~made ~~issued~~pursuant ~~3,800,000 restricted~~to ~~shares~~the ofshare ~~its~~repurchase ~~Common~~program ~~Stock~~authorized toby the ~~Sellers~~Company’s ~~(Note~~Board 1)of ~~valued at $5~~Directors.00 ~~per~~Following ~~share~~the ~~for~~transaction, a142,358 shares ~~total~~remain ~~fair~~authorized ~~value~~for ~~of $19,000,000~~repurchase.

During the year ended March 31, 2025, Orocidin A/S issued shares of its common stock in a capital raise with a third party in exchange for proceeds of $193,330. Aligned with the Company’s then ownership interest in Orocidin A/S, 5% of the proceeds, or $9,667, was allocated to noncontrolling interests while 95% of the proceeds, or $183,663, was allocated to additional paid-in capital. The capital raise reduced the Company’s ownership interest to approximately 94.7%.

On November 11, 2024, the Company entered into an agreement with Bio-Convert to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 shares of the Company’s Common Stock. The transaction was consummated on November 12, 2024 for a total consideration of $39,000,000, or $3.25 per share.

On November 12, 2024, the Company acquired the remaining 5.3% of the outstanding shares of Orocidin A/S through the issuance of 200,000 shares at $3.25 per share, or $443,708 of the Company’s Common Stock to the Orocidin A/S selling shareholders. Orocidin A/S is now a wholly owned subsidiary of the Company.

NOTE 9 - STOCK-BASED COMPENSATION

~~The~~In June 2024, the Company established the Nordicus Partners Corporation 2024 Stock Incentive Plan (the “Plan”). ~~This plan was effective on June 7, 2024 per the Board of Directors resolution.~~ The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key people with incentives to improve stockholder value and to contribute to the growth and financial success of the Company, and (ii) enabling the Company to attract, retain and reward the best-available persons.

The Plan permits the granting of stock options (including incentive stock options qualifying under Code Section 422 and nonqualified stock options), stock appreciation rights (SARs), restricted or unrestricted stock awards, restricted stock units, performance awards, other stock-based awards, or any combination of the foregoing.

Participation in the Plan shall be open to all employees, officers, directors, and consultants of the Company, or of any affiliate of the Company, as may be selected by the Company from time to time. However, only employees of the Company, and of any parent or subsidiary of the Company, shall be eligible for the grant of an incentive stock option. The grant of an award at any time to any person shall not entitle that person to a grant of an award at any future time.

The shares of Common Stock that may be issued with respect to awards granted under the Plan shall not exceed an aggregate of 7,000,000 shares of Common Stock. The maximum number of shares of Common Stock under the Plan that may be issued as incentive stock options shall be 7,000,000 shares. Regarding performance-based award limitations, the number of shares of Common Stock that may be granted in the form of options, SARs, restricted stock awards, restricted stock units, or performance award shares in a single fiscal year to a participant may not exceed 2,000,000 of each form.

F-1718

The following table summarizes the Company’s stock option activity under the Plan for the year ended March 31, ~~2025~~2026. Included in the 925,000 outstanding options are 375,000 performance-based awards and 550,000 service-based awards:

SCHEDULE OF STOCK OPTION

	Number of Stock Options		Weighted-average Exercise Price per Option*		Weighted-average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding as of March 31, 2024		—		—		—		—
Outstanding as of March 31, 2025		825,000	$	3.25		9.63		675,000
Granted		~~825~~100,000	$	31.2590		—		—
Outstanding as of March 31, 2025		825,000	$	3.25		9.63	$	675,000
Outstanding as of March 31, 2026		925,000	$	3.00		8.71		135,000
Exercisable and vested as of March 31, 2025		450,000	$	3.25		9.63	$	675,000
Exercisable and vested as of March 31, 2026		550,000	$	3.00		8.71		135,000
Vested and expected to vest as of March 31, 2025		450,000	$	3.25		9.63	$	675,000
Vested and expected to vest as of March 31, 2026		550,000	$	3.00		8.71		135,000

The weighted-average exercise price excludes the exercise price for the performance awards due to the variable nature of the exercise price. See below for more discussion of the performance awards.

~~During~~The ~~the~~stock-based ~~year~~compensation ~~ended~~expense ~~March~~related ~~31,~~to ~~2025,~~option ~~375,000~~grants ~~performance~~under ~~awards (~~the ~~“Performance~~Plan ~~Awards”)~~was ~~were issued~~$137,544, ~~whose~~for ~~vesting is dependent upon future events that were not deemed probable of occurring at~~ the ~~time~~year ofended ~~grant through~~ March 31, ~~2025.~~2026 ~~The~~and ~~exercise~~was ~~price of the~~recognized ~~Performance~~within ~~Awards~~officer ~~will~~compensation beon ~~equal to~~ the ~~closing price per share of the~~ Company’s ~~common~~consolidated ~~stock~~statement ~~on the trading day preceding the vesting date. The grant date fair value~~ of ~~the~~operations Performance Awards was $671,250. The Company did not recognize compensation expense for such awards as achievement of the milestone was not considered probable. The Company will reassess the probability of achievement at each reporting date and ~~will~~comprehensive ~~recognize compensation expense if and when the performance condition becomes probable of achievement~~loss.

~~The~~All ~~stock-~~of the service based ~~compensation~~awards ~~expense~~in the table above were fully vested at issuance and therefore all related tocompensation ~~option~~expense ~~grants~~was ~~under~~recognized in the ~~Plan~~periods the awards were granted. There was ~~$527,625~~no ~~for~~unrecognized compensation cost related to the ~~year~~service ~~ended~~based ~~March~~options as of March 31, ~~2025~~2026. The Performance Awards in the table above will fully vest when the vesting terms are met and ~~was~~expense will be recognized when ~~within~~the ~~officer~~vesting event becomes probable. Therefore, no stock-based compensation onexpense was recorded for the ~~Company’s~~Performance ~~consolidated~~Awards ~~statement~~for ofthe ~~operations~~year ended ~~and~~March ~~comprehensive~~31, ~~loss~~2026.

~~All~~In ofNovember ~~the~~2024, ~~service~~375,000 ~~based~~performance awards in (the ~~table~~“Performance ~~above~~Awards”) were ~~fully~~issued, ~~vested~~whose atvesting ~~issuance~~is ~~and~~dependent ~~therefore~~upon ~~all~~ events related ~~compensation~~to ~~expense~~future ~~was~~acquisitions ~~recognized during~~that were not deemed probable of occurring at the ~~year~~time ~~ended~~of grant through March 31, 2025. ~~There~~The ~~was~~exercise noprice of ~~unrecognized~~the ~~compensation~~Performance ~~cost~~Awards ~~related~~will be equal to the ~~service~~closing ~~based~~price ~~options~~per asshare of ~~March~~the ~~31,~~Company’s common stock on the trading day preceding ~~2025~~the vesting date. ~~The~~Due to the variability in the exercise price of the Performance Awards, inthat is the ~~table~~exercise ~~above~~price will ~~not~~be ~~fully~~equal ~~vested~~to the ~~until~~closing price per share on the ~~vesting~~date ~~event~~preceding ~~becomes~~the ~~probable.~~vesting ~~Therefore~~date, ~~all~~the ~~related compensation~~Company ~~expense~~concluded that the grant date was ~~unrecognized~~not established for accounting purposes. ~~There~~The fair value of the Performance Awards on the date of award was $671,250. ~~unrecognized~~As ~~compensation~~of ~~cost~~March ~~related~~31, to2026, the fair value of the Performance Awards was $924,000. The Company did not recognize compensation expense for such awards as the grant date has not been established nor is the achievement of ~~March~~the milestone considered probable. The Company will reassess the probability of achievement ~~31,~~at ~~2025~~each reporting date and will recognize compensation expense if and when the performance condition becomes probable of achievement.

The weighted-average grant date fair value per share of options granted during the year ended March 31, ~~2025~~2026 was $1.3938. ~~There~~The ~~were~~Company nouses the Black-Scholes option model to estimate the fair value of stock options. In applying the Black-Scholes option model, the Company used ~~exercised~~the ~~during~~following assumptions in the ~~year~~valuation ~~ended~~of ~~March~~options ~~31,~~granted ~~2025.~~in 2026:

~~The~~SCHEDULE ~~Company~~OF ~~uses~~FAIR ~~the~~VALUE ~~Black-Scholes~~STOCK option model to estimate the fair value of stock options. In applying the Black-Scholes option model, the Company used the following assumptions in the valuation of options granted during the year ended March 31, 2025 (other than the Performance Awards):OPTIONS

Expected volatility		92	%
Expected dividend yield		—	%
Exercise price	$	1.90
Stock price	$	1.90
Expected term (years)		5.0
Risk-free rate		3.80	%

F-19

Due to the variability of the exercise price, which will be equal to the closing price per share of the Company’s common stock on the trading day preceding the vesting date, the Company uses a Monte Carlo simulation model to estimate the fair value of the 375,000 Performance Awards where vesting was not probable as of March 31, 2026. In applying the Monte Carlo simulation model, the Company used the following assumptions in the valuation of the Performance Awards as of March 31, 2026:

SCHEDULE OF FAIR VALUE OF STOCK OPTIONS

	Year Ended March 31, 2025
Exercise price	Variable
Expected volatility		40.0	%
Contractual term (years)		8.63
Expected dividend yield		—	%
Volatility (annual)		73	%
Exercise price	$	3.25
Risk-free rate		4.1	%
Stock price	$	2.83
Dividend yield (per share)		0	%
Expected term (years)		5.0
Risk-free rate		4.30	%

~~F-18~~Equity issued for consulting services

~~Due to~~ For the ~~variability~~years ofended ~~the~~March ~~exercise price~~31, ~~which~~2026 ~~will~~and be2025, ~~equal~~unrelated to the ~~closing~~Plan, ~~price per share of~~ the Company~~’s common~~ ~~stock~~issued on84,000 ~~the~~and ~~trading day preceding the vesting date~~30,000 ~~the Company~~shares ~~uses~~of ~~the~~Common ~~Monte~~Stock ~~Carlo simulation model~~ to ~~estimate~~a ~~the~~third party ~~fair~~for ~~value~~consulting ofservices, ~~Performance~~respectively, ~~Awards.~~which Inwere ~~applying~~valued ~~the~~at ~~Monte~~$304,000 ~~Carlo~~and ~~simulation model~~$138,979, ~~the~~respectively, ~~Company~~and ~~used~~recorded ~~the~~with ~~following~~general ~~assumptions in the valuation of the Performance Awards granted during the year ended March 31,~~and ~~2025:~~administrative expense.

~~SCHEDULE~~NOTE OF10 ~~FAIR~~- ~~VALUE~~GOODWILL OFAND ~~STOCK~~INTANGIBLE ~~OPTIONS~~ASSETS

	Year Ended March 31, 2025
Exercise price		Variable
Contractual term (years)		10
Volatility (annual)		54	%
Risk-free rate		4.3	%
Dividend yield (per share)		0	%

Awards issued for consulting services

Unrelated to the Plan, during the year ended March 31, 2025, the Company issued 30,000 shares of Common Stock to a third party for consulting services, which were valued at $138,979.

Effective November 27, 2024, the Company entered into a consulting agreement with an advisory firm that will continue through November 30, 2025. As part of compensation for the consulting services, the Company issued to the counterparty 61,500 restricted stock units (“RSUs”), each of which representing one share of Common Stock per unit, subject to vesting conditions as follows: (i) 15,300 units vesting 45 days following the effective date and (ii) thereafter, monthly tranches of 4,200 units that vest at the completion of each additional month of service rendered. The fair value of the RSUs on the grant date was determined to be $175,275 based on the Company’s stock price on that date of $2.85. The Company recognized $55,575 in stock-based compensation in consulting expense on the consolidated statement of operations and comprehensive loss related to the vesting of the 19,500 RSUs during the year ended March 31, 2025. The RSUs were granted outside of the Plan. On February 27, 2025, the Company terminated its agreement. As of the date of termination, the remaining 42,000 unvested RSUs were forfeited as of that date.

As of March 31, 2025, there was no unrecognized equity-based compensation expense related to the RSUs.

A summary of the Company’s RSU activity for the year ended March 31, 2025 is as follows:

SCHEDULE OF RSU ACTIVITY

	Number of Shares			Weighted-Average Grant Date Fair Value
Unvested at March 31, 2024		—		$	—
Granted		61,500			2.85
Vested		(19,500	)		2.85
Forfeited		(42,000	)		2.85
Unvested at March 31, 2025		—		$	—

On June 17, 2024, the Company’s board of directors cancelled the Company’s 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”). At the time there were no stock awards of any kind outstanding under the 2017 Plan.

NOTE 10 - BUSINESS COMBINATIONS

Orocidin A/S

On May 13, 2024, the Company and certain shareholders of Orocidin ~~A/S~~, a Danish stock corporation entered into a Stock Purchase and Sale ~~Agreement~~ Agreement (“Business Combination”), under which the Company issued 3,800,000 restricted shares of its Common Stock to the Sellers in exchange for 95% of Orocidin’s outstanding shares of capital stock. The shares were valued at $5.00, the closing stock price of the Company on the date of acquisition.

Orocidin ~~A/S~~ is a preclinical-stage biotechnology company, and is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis.

The Company accounted for the transaction as a business combination under ASC 805 and as a result, allocated the fair value of identifiable assets acquired and liabilities assumed as of the acquisition date ~~as outlined in the table below~~. The excess of the purchase price over the estimated fair values of the underlying identifiable assets acquired, liabilities assumed was allocated to goodwill.

FThe $15,680,760 of acquired intangible assets was assigned to IPR&D assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-19Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Orocidin’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Orocidin’s research and development activities related to its next generation of periodontitis therapies.

~~During~~On ~~the~~November ~~quarter ended March 31~~11, ~~2025~~2024, the Company ~~completed~~acquired ~~its determination of~~ the ~~fair~~remaining ~~values of purchase consideration~~29,663 ~~inclusive~~outstanding ~~of non-cash~~common ~~consideration~~shares ~~paid by the Company~~ and ~~the~~voting ~~fair value of non-controlling~~ interest, ~~and~~or ~~in-process~~5.34%, ~~research~~of ~~and development~~Orocidin. The ~~measurement~~acquisition-date ~~period~~fair ~~adjustment~~value ~~resulted~~of inthe ~~(i)~~consideration atransferred totaled $~~450~~650,000, ~~net~~which ~~increase~~consisted inof ~~total consideration paid~~200,000 ~~(ii)~~shares aof ~~$15,457,444~~the ~~increase in~~Company’s ~~in-process~~Common ~~research~~Stock. ~~and~~The ~~development~~fair ~~recorded,~~value ~~and (iii) recognition~~ of athe $3200,~~449,767~~000 ~~deferred~~common ~~tax~~shares ~~liability~~issued ~~associated with~~was ~~the~~determined ~~in-process~~based ~~research~~on ~~and~~the ~~development~~closing ~~asset.~~market ~~The~~price ~~net effect~~ of ~~such~~the ~~measurement~~Company’s Common ~~period~~Stock ~~adjustments~~on ~~was~~the ~~recorded~~acquisition asdate, ~~an adjustment to goodwill~~$3.25.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date.

SCHEDULE OF PURCHASE PRICE AND ESTIMATED MARKET VALUE OF THE ASSETS ACQUIRED LIABILITIES

Cash	$	134,572
In-process research and development		15,680,760
Other receivables		28,872
Total identifiable assets acquired		15,844,204
Accounts payable and accruals		(29,779	)
Deferred tax liability		(3,449,767	)
Liabilities assumed		(3,479,546	)
Net identifiable assets acquired		12,364,658
Goodwill		7,085,342
Non-controlling interest		(450,000	)
Net assets acquired	$	19,000,000

The $15,680,760 of acquired intangible assets was assigned to IPR&D assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Orocidin’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Orocidin’s research and development activities related to its next generation of periodotitis therapies.

The goodwill recognized is attributable primarily to expected synergies and the assembled workforce of Orocdin. None of the goodwill is expected to be deductible for income tax purposes. As of March 31, 2025, upon completing the valuation of IPR&D during the remeasurement period, there was a reduction in the initial recognized amounts of goodwill resulting from the acquisition of Orocidin.

The Company recognized $4,560 of acquisition related costs that were expensed during the year ended March 31, 2025. These costs are included in the consolidated statement of operations in the line item entitled professional fees.

From the closing date of the Business Combination through March 31, 2025, Orocidin A/S has no revenue and incurred $1,186,410 in net losses.

On November 11, 2024, the Company acquired the remaining 29,663 outstanding common shares and voting interest, or 5.34%, of Orocidin. The acquisition-date fair value of the consideration transferred totaled $650,000, which consisted of 200,000 shares of the Company’s Common Stock. The fair value of the 200,000 common shares issued was determined based on the closing market price of the Company’s Common Stock on the acquisition date, $3.25. On this acquisition date, the Company derecognized the carrying value of the noncontrolling interest in Orocidin of $443,708. The difference between the amount of the consideration transferred and the carrying amount of the noncontrolling interest was recognized within additional paid-in capital on the consolidated balance sheet.

F-20

The following represents the pro forma consolidated revenue and net loss attributable to Nordicus Partners Corporation as if Orocdin had been included in the consolidated results of the Company for years ended March 31, 2025 and 2024:

SCHEDULE OF PROFORMA CONSOLIDATED REVENUE

	2025			2024
	For the Years Ended
	March 31,
	2025			2024
Revenue	$	2,500		$	2,500
Net loss attributable to Nordicus Partners Corporation	$	(2,991,780	)	$	(364,243	)

Prior to the acquisition, the Company had a preexisting relationship with Orocidin, in which the Company provided consulting services to Orocidin to accelerate the company and achieve certain milestones prior to the acquisition. At the date of the acquisition, the Company had earned consulting fees in the amount of $2,500 for services provided prior to the acquisition. Transactions between the two entities subsequent to the acquisition have been eliminated in consolidation on the Company’s consolidated financial statements.

Bio-Convert A/S

On November 11, 2024 (the acquisition date), the Company acquired 100% of the outstanding common shares and voting interest of Bio-Convert ~~A/S (“Bio-Convert”)~~. ~~The results of Bio-Convert’s operations have been included in the consolidated financial statements~~ ~~since that date.~~ The Company accounted for the transaction as a business combination under ASC 805.

Bio-Convert is a Denmark-based preclinical-stage biotechnology company focused on revolutionizing the treatment of oral leukoplakia, which is a potentially malignant disorder affecting the oral mucosa. Oral leukoplakia is a white patch or plaque that can develop in the oral cavity and when accompanied by dysplasia, it becomes a marker of disease progression and patients can potentially develop oral cancer. Bio-Convert is developing a new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation. This is achieved through a proprietary mucoadhesive oral topical formulation that delivers the drug without any systemic absorption. The aim of the treatment is therefore to eliminate the lesions or to reduce the malignant conversion rate of oral leukoplakia to oral cancer. The effect on oral cancer may improve the surgical removal procedure should this be needed for the oral cancer patients. Bio-Convert’s current plan is to conduct a pilot efficacy study in patients with oral leukoplakia.

F-20

The acquisition-date fair value of the consideration transferred totaled $39,000,000, which consisted of 12,000,000 shares of the Company’s Common Stock. The fair value of the 12,000,000 common shares issued was determined based on the closing market price of the Company’s Common Stock on the acquisition date, $3.25.

During the quarter ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration, inclusive of non-cash consideration paid by the Company and in-process research and development. The measurement period adjustment resulted in (i) a $26,475,819 increase in in-process research and development recorded and (ii) recognition of a $5,868,647 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date.

SCHEDULE OF PURCHASE PRICE AND ESTIMATED MARKET VALUE OF THE ASSETS ACQUIRED LIABILITIES

	November 11, 2024
Cash		23,976
In-process research and development		26,675,670
Prepaid expenses		7,500
Total identifiable assets acquired		26,707,146
Accounts payable and accrued expenses		(4,181	)
Deferred tax liability		(5,868,647	)
Total liabilities assumed		(5,872,828	)
Net identifiable assets acquired		20,834,318
Goodwill		18,165,682
Net assets acquired	$	39,000,000

The $26,675,670 of acquired intangible assets was assigned to in-process research and development assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Bio-Covert’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Bio-Convert’s research and development activities related to its new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation.

~~F-21~~The following table summarizes the goodwill activity for the year ended March 31, 2026:

The goodwill recognized is attributable primarily to expected synergies and the assembled workforce of Bio-Convert. None of the goodwill is expected to be deductible for income tax purposes. As of March 31, 2025, upon completing the valuation of IPR&D during the remeasurement period, there was a reduction in the initial recognized amounts of goodwill resulting from the acquisition of Bio-Convert.

The Company recognized $5,880 of acquisition related costs that were expensed during the year ended March 31, 2025. These costs are included in the consolidated statement of operations in the line item entitled professional fees. The Company also recognized $2,880 in costs associated with issuing and registering the shares issued as consideration in the business combination. Those costs were deducted from the recognized proceeds of issuance within stockholders’ deficit.

The amounts of revenue and net loss of Bio-Convert included in the Company’s consolidated statement of operations and comprehensive loss were zero and $330,738, respectively, from the acquisition date to year ended March 31, 2025.

The following represents the pro forma consolidated revenue and net loss attributable to Nordicus Partners Corporation as if Bio-Convert had been included in the consolidated results of the Company for years ended March 31, 2025 and 2024:

SCHEDULE OF PROFORMA CONSOLIDATED REVENUE

	2025			2024
	For the Years Ended
	March 31,
	2025			2024
Revenue	$	2,500		$	2,500
Net loss attributable to Nordicus Partners Corporation	$	(2,975,856	)	$	(300,953	)

Prior to the acquisition, the Company had a preexisting relationship with Bio-Convert, in which the Company provided consulting services to Bio-Convert to accelerate the company and achieve certain milestones prior to the acquisition. At the date of the acquisition, the Company had earned consulting fees in the amount of $2,500 for services provided prior to the acquisition. Transactions between the two entities subsequent to the acquisition have been eliminated in consolidation on the Company’s consolidated financial statements.

The following table summarizes the goodwill activity for the year ended March 31, 2025:

SCHEDULE OF GOODWILL

	Orocidin	~~Orocidin~~		Bio-Convert		Total
March 31, 2024	$	—		$	—	$	—
Balance as of March 31, 2025	$	7,084,829		$	18,405,922	$	25,490,751
Goodwill recognized in acquisition		7,085,342			18,165,682		25,251,024
Foreign currency translation adjustment		464,225			1,206,024		1,670,249
Foreign currency translation adjustment		(513	)		240,240		239,727
Balance as of March 31, 2026	$	7,549,054		$	19,611,946	$	27,161,000
March 31, 2025	$	7,084,829		$	18,405,922	$	25,490,751

The following table summarizes the in-process research and development activity for the year ended March 31, ~~2025~~2026:

	Orocidin			Bio-Convert		Total
March 31, 2024	$	—		$	—	$	—
Balance as of March 31, 2025	$	15,679,626		$	27,028,453	$	42,708,079
In-process research and development recognized in acquisition		15,680,760			26,675,670		42,356,430
Foreign currency translation adjustment		1,027,387			1,771,005		2,798,392
Foreign currency translation adjustment		(1,134	)		352,783		351,649
Balance as of March 31, 2026	$	16,707,013		$	28,799,458	$	45,506,471
March 31, 2025	$	15,679,626		$	27,028,453	$	42,708,079

F-22

NOTE 11 - WARRANTS

A summary of the Company’s outstanding warrant activity for ~~the~~ year ended March 31, ~~2025~~2026 is as follows:

SCHEDULE OF WARRANT ACTIVITIES

				~~Weighted~~		Weighted ~~Average~~
				Average		Remaining		Aggregate
				Weighted		Average
	Number of			Average Exercise		Remaining Contract		~~Intrinsic~~
	Warrants			Price		Term		~~Value~~
Outstanding, March 31, 2024		632,900		$	10.00		1.35	$	—
Outstanding, March 31, 2025		75,000		$	10.00		2.75
Issued		~~1,000,000~~—			~~8.91~~—		~~1.00~~—		—
Expired/cancelled		~~(1,465,124~~—	)		~~9.28~~—		—		—
Exercised		~~(92,776~~—	)		~~9.59~~—		—		—
Outstanding, March 31, 2025		75,000		$	10.00		2.75	$	—
Outstanding, March 31, 2026		75,000		$	10.00		1.75

All of the outstanding warrants are exercisable as of March 31, ~~2025~~2026 with an intrinsic value of $0.

NOTE 12 - INCOME TAX

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated Staff Accounting Bulletin No. 118 regarding the impact of the decreased tax rates of the Tax Cuts & Jobs Act. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company and its subsidiaries file income tax returns in the U.S. and foreign jurisdictions. The U.S. federal and foreign jurisdiction income tax rates of 21% and 22%, respectively, are being used.

F-21

For financial reporting purposes, loss before provision for income taxes, includes the following components:

	March 31, 2025			March 31, 2024
	March 31, 2026			March 31, 2025
Domestic	$	(1,~~378~~279,~~769~~724	)	$	(~~298~~1,~~202~~378,769	)
Foreign		(12,~~538~~767,~~511~~080	)		—(1,538,511	)
Loss before income taxes	$	(24,~~917~~046,~~280~~804	)	$	(~~298~~2,~~202~~917,280	)

~~Reconciliation~~The ~~between~~table ~~our~~below provides the updated requirements of ASU 2023-09 for 2025. See Notes to Consolidated Financial Statements - Income Taxes for additional details on the adoption of ASU 2023-09. The effective tax rate ~~and~~differs from the ~~United~~federal ~~States~~ statutory income tax rate isapplied to asthe ~~follows~~loss before provision for income taxes and tax due to the following:

	March 31, 2026
	Amount			Rate
Federal tax benefit	$	(188,090	)		(21.0	)%
Foreign expense (benefit)		3,830			0.4	%
Temporary differences		(39,366	)		(4.4	)%
Valuation allowance change		223,626			25.0	%
Total income tax expense	$	—			—	%

As previously disclosed for the year ended March 31, 2025, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:

	March 31, 2025			~~March 31, 2024~~
Federal statutory tax rate		21.0	%		~~21.0~~	%
Foreign rate differential		0.5	%		—
Permanent differences		(4.7	)%		—
Increase in valuation allowance		(16.8	)%		~~(21.0~~	)
Effective tax rate		—	%		—	%

~~A reconciliation of taxes on the income computed at the U.S. federal statuary rate to the amounts provided as follows:~~F-22

~~SCHEDULE~~The OFtax ~~RECONCILIATION~~effects OFof ~~TAXES~~temporary ONdifferences ~~THE~~that ~~INCOME~~give rise to significant portions of the Company’s deferred tax assets and deferred tax liabilities consist of the following:

	March 31, 2025			March 31, 2024
Tax provision computed at the federal statutory rate	$	(612,629	)	$	(60,169	)
Different tax rates applicable to foreign operations		(15,385	)		—
Permanent differences		137,358
Valuation allowance		490,656			60,169
Provision for income tax	$	—		$	—

Significant components of the Company’s deferred tax assets and deferred tax liabilities consist of the following:

	March 31, 2025			March 31, 2024
	March 31, 2026			March 31, 2025
Deferred Tax Assets:
Net operating loss carryforwards	$	5,253,078		$	2,375,300
Stock-based compensation	$	28,884		$	—
Total gross deferred tax assets	$	5,253,078		$	2,375,300
Net operating loss carryforwards		5,302,399			5,253,078
Valuation allowance	$	(5,253,078	)	$	(2,375,300	)
Total gross deferred tax assets		5,331,283			5,253,078
Valuation allowance		(5,331,283	)		(5,253,078	)
Net deferred tax assets	$	—		$	—
Deferred Tax Liabilities:
In-process research and development intangible assets	$	(9,318,414	)	$	—(9,318,414	)
Total deferred tax liabilities		(9,318,414	)		—(9,318,414	)
Net deferred tax liability	$	(9,318,414	)	$	—(9,318,414	)

At March 31, 2026 and 2025, the Company had net operating loss carry forwards of approximately $25,190,000 and $24,941,000, respectively, that may be offset against future taxable income. During the years ended March 31, ~~2025~~2026 and ~~2024~~2025, the total change in the valuation allowance was $~~490~~223,~~656~~ 626 and $60490,~~169~~656, respectively. Net operating loss carryforwards of approximately $2120,~~592~~762,~~000~~400 can be carried forward for 20 years and begin to expire in 2024. Net operating loss carryforward amounts of $310,~~349~~732,~~000~~500 can be carried forward indefinitely, but are limited to 80% of taxable income in any one year. The Company has net operating loss carryforwards that have resulted in deferred tax assets of approximately $5,302,399, of which $930,000 have no expiration date. The Company maintains certain earnings as indefinitely reinvested in operations outside of the United States, for which no deferred income taxes have been provided. Determination of the amount of unrecognized deferred tax liability, if any, associated with such earnings is not practicable. No tax benefit has been reported in the March 31, ~~2025~~2026, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. A portion of the Company’s deferred tax liability, totaling $735,953, relates to the income tax effect of foreign currency translation adjustments on its foreign subsidiaries, which was recorded through other comprehensive income

The Company’s ability to use its net operating loss carryforwards may be substantially limited due to ownership change limitations that may occur as required by Section 382 of the Internal Revenue Code of 1986 as amended. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since incurring losses. If the Company has completed an ownership change, utilization of the net operating loss carryforwards would be subject to annual limitations under Section 382. Any limitation could result in expiration of a portion of the net operating loss carryforwards before utilization. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2016.

NOTE 13 - NOTE PAYABLE

On February 18, 2026, Nordicus Partners Corporation entered into a demand promissory note (the “Note”) with Reddington, in the aggregate amount of $40,000. The Note bears interest at a rate equal to the lesser of 6.0% per annum and the maximum rate permitted by applicable law. Interest is calculated on the basis of a 365-day year and actual days elapsed.

The outstanding principal balance, together with all accrued and unpaid interest, is due and payable on demand by the Lender and, accordingly, is classified as a current liability on the balance sheet. In the event of default, including nonpayment or certain insolvency events, the Payee may declare all amounts immediately due and payable and may pursue customary remedies, including collection costs and attorneys’ fees. The Company may prepay the Note, in whole or in part, at any time without premium or penalty. Payments made under the Note are applied first to accrued interest and then to principal.

On March 6, 2026, the Company entered into an additional demand promissory note with the same lender under substantially identical terms, pursuant to which the Company borrowed an additional $20,000.

F-23

~~NOTE~~As 13of -March ~~SEGMENT~~31, ~~REPORTING~~2026 and 2025, the principal balance due was $60,000 and $0, respectively. The Company recorded accrued interest expense of $345 and $0 for the years ended March 31, 2026 and 2025, respectively, which is included in accounts payable and accrued expenses on the consolidated balance sheets.

~~The~~NOTE ~~Company~~14 ~~operates as a single operating segment, which consists of Orocidin and Bio~~-~~Convert~~ ~~wholly-owned~~SEGMENT ~~subsidiaries that are focused on developing medicines supporting oral health. The Company has one reportable segment, which consists of its single operating segment.~~REPORTING

The Company operates as a single operating segment, which consists of the Company’s wholly-owned subsidiaries, Orocidin and Bio-Convert, and its majority-owned subsidiary, NoviThera. All subsidiaries are focused on developing medicines supporting oral health. The Company has one reportable segment, which consists of its single operating segment.

The accounting policies of the segment are the same as those described in the summary of significant accounting policies.

The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). When evaluating the Company’s financial performance and deciding how to allocate resources, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company -wide basis. The Company’s CODM uses net loss to evaluate past spending and to guide decisions of future spending. Net loss is used to monitor budget versus actual results.

The Company did not generate any ~~material~~ revenue during the ~~years~~year ended March 31, ~~2025 and 2024~~2026. The Company has no material intra-entity ~~sales.~~ revenues or expenses. As the Company is currently in the pre-revenue phase, the aforementioned operating expenses are the primary drivers that guide ~~decisions~~ decisions of future spending and to monitor performance.

The measure of segment assets is reported on the balance sheet as total assets.

The CODM does not separately evaluate performance by geographic region or product line, as the Company has not yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company’s operations are conducted within the United States of America and Denmark.

NOTE 1415 - SUBSEQUENT EVENTS

Management has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following:

~~Effective~~In ~~April~~March and ~~May~~April ~~2025~~2026, the Company issued to ~~two~~five private investors for a total of 54201,~~000~~ 500 restricted shares of its common stock, par value $0.01001 per share. The price per share was $52.~~00. On June 11, 2025, the Company closed the private offering of such shares~~ 75 for gross proceeds of $~~270,000~~0.6 million.

~~Effective~~In ~~June~~March ~~2025,~~through ~~the~~June ~~Company~~2026 ~~issued~~an toaffiliate aof ~~private~~our ~~investor~~chief aexecutive ~~total of 35~~officer,~~000~~ ~~restricted~~Henrik ~~shares of its common stock~~Rouf, ~~par~~loaned ~~value~~to ~~$0.01~~the ~~per~~company ~~share. The price per share was~~ $~~4.00. On June 30~~22,000 ~~2025,~~pursuant ~~the~~to ~~Company~~demand ~~closed~~promissory notes ~~the~~bearing ~~private~~interest ~~offering~~at of6% ~~such~~per ~~shares for gross proceeds of $140,000~~annum.

On ~~June~~July 307, ~~2025~~2026, ~~our~~Andrew ~~Board of Directors approved a third amended employment agreement for our chief executive officer, Henrik Rouf, and a third amended consulting agreement for our chief financial officer, Bennett~~ J. ~~Yankowitz.~~Ritter ~~Mr.~~resigned ~~Rouf’s~~from ~~employment~~the ~~agreement~~Board ~~as amended~~of ~~provides~~Directors ~~for a base salary~~ of ~~$360,000~~the ~~per year~~Company, ~~commencing~~effective ~~July~~immediately. 1,He ~~2025,~~also ~~and~~resigned ~~has~~from ~~a term of one year. Mr. Yankowitz’s consulting~~the ~~agreement~~Audit ~~as amended provides for a base salary of $120~~Committee,~~000~~ ~~per~~Compensation ~~year,~~Committee ~~commencing~~and ~~July~~Nominating ~~1, 2025,~~ and ~~has~~Corporate aGovernance ~~term~~Committee of ~~one~~the ~~year~~Board.

Effective July 2025, the Company issued to certain private investors a total of 145,600 restricted shares of its common stock, par value $0.01 per share. The price per share was $1.90 for gross proceeds of $276,640.

F-24

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Our management, with the participation of our chief executive officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures ~~Controls~~include, without limitation, controls and ~~Procedures~~procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer concluded that our disclosure controls and procedures as of March 31, 2026, were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions. If successful in effecting a transaction with an operating company, we intend to take appropriate and reasonable steps to make improvements to remediate these deficiencies.

Our management, with the participation of our chief executive officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2025. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer concluded that our disclosure controls and procedures as of March 31, 2025, were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions. If successful in effecting a transaction with an operating company, we intend to take appropriate and reasonable steps to make improvements to remediate these deficiencies.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934). A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the interim or annual financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management, with the participation of our Chief Executive Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, ~~2025~~2026, based on the framework in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control (2013). Based on this assessment, our management concluded that, as of March 31, ~~2025~~2026, our internal controls over financial reporting were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions. If successful in effecting a transaction with an operating company, we intend to take appropriate and reasonable steps to make improvements to remediate these deficiencies.

This annual report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Securities and Exchange Commission rules that permit us to provide only management’s report in this annual report.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the quarter ended March 31, ~~2025~~2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

~~PART~~Part III

Item 10. Directors, Executive Officers and Corporate Governance

The following persons served as our directors and executive officers for the fiscal years ended March 31, ~~2025~~2026 and ~~2024~~2025. Each director holds office until the next annual meeting of the stockholders or until his successor has been duly elected and qualified. Each executive officer serves at the discretion of the Board of Directors of the Company.

Name	Age	Position
Henrik Rouf	5859	Chief Executive Officer
Christian Hill-Madsen (1)	5960	Director
Bennett J. Yankowitz	7071	Director and Chief Financial Officer
Henrik Keller	70	Director
Henrik Keller (2)	71	Director
Peter Severin (2)	61	Director
Peter Severin (3)	62	Director
Torben S. Jensen (4)	61	Director
Kim T. Mücke (4)	61	Director
Andrew J. Ritter (5)	43	Director (resigned effective July 7, 2026)

	(1)	Resigned from the Board on June 3, 2024.
	(2)	~~Appointed~~Resigned tofrom the Board on ~~June~~August 37, ~~2024~~2025.
	(3)	Appointed to the Board on June 3, 2024.
	(4)	Appointed to the Board on August 7, 2025.
	(5)	Appointed to the Board on August 7, 2025, resigned effective July 7, 2026.

There are no family relationships between our directors and executive officers.

Background of Executive Officers and Directors

Henrik Rouf—Chief Executive Officer. Mr. Rouf has 30 years of experience in the global financial markets, working as an investment banker and international financier. He currently advises public and private companies in various industries, including life sciences, AI, blockchain, and semiconductors, throughout North America, Europe, and India.

Prior to joining Nordicus Partners as Chief Executive Officer, Mr. Rouf was the President of PWP, Inc., a California-based merchant bank, from 2004 to 2023, where he ran the company’s overall investment banking practice. During this time, he also cofounded Rocketfuel Blockchain, a global payment processing platform. From 1997 to 2004, he was the Managing Partner of Impact Capital and financed numerous micro-cap and small-cap companies. Mr. Rouf started his career in the U.S. in 1991 as an Institutional Broker for various brokerage houses in New York and San Francisco, including Wedbush.

Peter Severin – Chairman of our Board of Directors. Mr. Severin is an experienced consultant in the pharmaceutical industry. He is the owner of Severin-Partners A/S, a consulting company based in Copenhagen, Denmark. He was previously head of sales for Novartis and Sales Manager at AstraZeneca Pharmaceuticals and at GlaxoSmithKline.

Christian Hill-Madsen—Former Chairman of our Board of Directors. Mr. Hill-Madsen joined the Nordicus Partners Corporation Board in January 2023. He has over 25 years of experience working as a headhunter dedicated to the Life Science Industry in the Nordics, mastering the fine art of finding the best candidates for the right job, in all aspects of the healthcare solution program from Headhunting and Recruitment, Salesforce Optimization, Assessment to Organizational Development, etc. He was the CEO of Life Science Power House ApS, a Denmark-based life science advisory and consultancy firm, from 2018 to 2023. From 2013 to 2018 he was the Founder and CEO of the life science headhunting firm, Hill-Consult.

Henrik Keller – Director. Mr. Keller has more than four decades of experience in the corporate sector, in which he has a proven track record of delivering excellent performances. Mr. Keller possesses a unique set of strategical, managerial and sales capabilities, which has been key in the documented success he has delivered to the companies he has been, and are currently involved with, serving in various positions as Owner, General Manager, Sales Manager, Consultant/Advisor, Board Member. He has been an independent business consultant since 2009. Through his professional career, Mr. Keller has established a network which spans globally.

19Bennett J. Yankowitz—Chief Financial Officer and Director. Mr. Yankowitz has more than 30 years of experience as a corporate attorney with leading law firms, specializing in securities, financial and merger and acquisition transactions, and has a background in financial analysis and real estate investment and development. He is of counsel to the law firm Shumaker Mallory LLP, and was previously of counsel to its predecessor firm Parker Shumaker Mills LLP. He is also chief executive officer of Gold Vault Capital, LLC. He was previously counsel to Kaye Scholer LLP and a partner of Heenan Blaikie and of Stroock & Stroock & Lavan LLP. From 2002 to 2014, he was a director of Proteus Energy Corporation, a California-based private oil and gas production and development company and was its Chief Executive Officer from 2008 to 2014. He was chief financial officer and a member of the board of directors of RocketFuel Blockchain, Inc. from 2015 to 2025. Mr. Yankowitz earned his B.A. degree in Mathematics from the University of California, Berkeley (1977), his J.D. degree from the University of Southern California (1980), where he was an editor of the Southern California Law Review, and his LL.M. degree (First Class Honours) from the University of Cambridge (1981), where he was an Evan Lewis-Thomas Scholar at Sidney Sussex College. He is a member of the California and New York bars.

Bennett J. Yankowitz—Chief Financial Officer and Member of our Board of Directors. Mr. Yankowitz has more than 30 years of experience as a corporate attorney with leading law firms, specializing in securities, financial and merger and acquisition transactions, and has a background in financial analysis and real estate investment and development. He is of counsel to the law firm Shumaker Mallory LLP, and was previously of counsel to its predecessor firm Parker Shumaker Mills LLP. He was previously counsel to Kaye Scholer LLP and a partner of Heenan Blaikie and of Stroock & Stroock & Lavan LLP. From 2002 to 2014, he was a director of Proteus Energy Corporation, a California-based private oil and gas production and development company and was its Chief Executive Officer from 2008 to 2014. He is currently chief financial officer and a member of the board of directors of RocketFuel Blockchain, Inc. Mr. Yankowitz earned his B.A. degree in Mathematics from the University of California, Berkeley (1977), his J.D. degree from the University of Southern California (1980), where he was an editor of the Southern California Law Review, and his LL.M. degree (First Class Honours) from the University of Cambridge (1981), where he was an Evan Lewis-Thomas Scholar at Sidney Sussex College. He is a member of the California and New York bars.

Our Board has concluded that Mr. Yankowitz is an appropriate person to represent management on our Board of Directors given his position as our Chief Financial Officer, his professional credentials, and his understanding of corporate regulatory matters and merger and acquisition activities.

Torben Jensen—Director. Mr. Jensen has more than 35 years of experience in finance and has during the years developed and funded projects and companies in real estate, energy, venture, life science and medico. He has previously been CEO and Chairman of the Board of two listed companies on Nasdaq. From 2019 to 2024 he was a Senior Partner in GK Partners ApS, a corporate finance house and a major shareholder in the Company, where he was the head of funding for projects. Furthermore, he has served as the Chief Executive Officer of AC Nordic since December 2024, also a major shareholder in the Company.

Kim T. Mücke—Director. Mr. Münke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) from 2002 to 2022 where he, among others, served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From January 1, 2025, Mr. Mücke has started as independent advisor, specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.

Andrew J. Ritter—Director (Resigned). Mr. Ritter has served as the Chief Executive Officer and a director of Cairns Health, an innovator in AI-powered remote care solutions supporting home and senior care, since September 2023. Previously, Mr. Ritter was the Chief Executive Officer of Docbot, an AI-driven MedTech company, from January 2021 to December 2022. He also founded and served as Chief Executive Officer of Ritter Pharmaceuticals, a biotechnology company focusing on gastrointestinal diseases, from March 2004 to May 2020. In addition, he served as a founding director of Myosin Therapeutics, a biotech spin-out from Scripps Research, from October 2021 to January 2025. Mr. Ritter earned a B.A. in political science at the University of Southern California and a Master of Business Administration at the Wharton School, University of Pennsylvania. On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors of the Company, effective immediately.

Code of Conduct and Ethics

We have adopted a Code of Ethics that allows for us to ensure that our disclosure controls and procedures remain effective. Our Code also defines the standard of conduct expected by our chief executive officer and director. A copy of our Code of Ethics will be furnished without charge to any person upon written request. Requests should be sent to: Chief Executive Officer, Nordicus Partners Corporation, 280 S. Beverly Dr., Suite 505, Beverly Hills, California 90212.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our securities to file reports of ownership and changes in ownership with the SEC. Based solely on a review of copies of such forms submitted to us, we believe that all persons subject to the requirements of Section 16(a) filed such reports on a timely basis in fiscal year ~~2025~~2026.

Corporate Governance and Guidelines

Our Board of Directors has long believed that good corporate governance is important to ensure that we manage our company for the long-term benefit of stockholders. During the past year, our Board of Directors has continued to review our governance practices in light of the Sarbanes-Oxley Act of 2002 and recently revised SEC rules and regulations. We intend to implement internal corporate governance guidelines and practices when we have available resources to implement these guidelines and practices. Such guidelines and practices, when implemented, will be furnished without charge to any person upon written request. Requests should be sent to: Chief Executive Officer, Nordicus Partners Corporation, 280 S. Beverly Dr., Suite 505, Beverly Hills, California 90212.

Committees of the Board of Directors

WeOn ~~currently~~November ~~have~~10, no2025, ~~separate~~the ~~audit,~~Board ~~compensation,~~created or(1) ~~nominating~~a ~~committees.~~Nominating ~~The~~and ~~entire~~Corporate ~~Board~~Governance ~~oversees~~Committee, ~~our~~consisting of Peter Severin (iChairman), ~~audits~~Kim T. Mücke and ~~auditing~~Andrew ~~procedures~~J. Ritter; (ii2) ~~compensation~~an ~~philosophies~~Audit ~~and objectives~~Committee, ~~establishment~~consisting of ~~remuneration~~Kim ~~levels~~T. ~~for~~Mücke ~~our~~(Chairman), ~~executive~~Peter ~~officer,~~Severin and ~~implementation~~Andrew ~~of our~~J. ~~incentive programs~~Ritter; and (~~iii~~3) ~~identification~~a Compensation Committee, consisting of ~~individuals~~Andrew ~~qualified~~J. toRitter ~~become~~(Chairman), ~~Board~~Peter ~~members~~Severin and ~~recommendation~~Kim toT. ~~our~~Mücke. ~~shareholders~~The Board also adopted a Code of ~~persons~~Conduct toand beEthics, ~~nominated~~an ~~for~~Insider ~~election~~Trading asPolicy, ~~directors~~a Whistleblower Policy and a Compensation Recovery Policy.

On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors of the Company, effective immediately. He also resigned from the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board.

Director Independence

We are not currently subject to listing requirements of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the Board be “independent” and, as a result, we are not at this time required to have our Board comprised of a majority of “Independent Directors.” As of the date of this Report, two of our directors are considered to be independent.

Item 11. Executive Compensation

Summary Compensation Table

The following table provides information concerning compensation for services rendered to us in all capacities for the fiscal years ended March 31, ~~2025~~2026 and ~~2024~~2025 by our named executive officer and former named executive officer.

Named Executive Officer	Fiscal Year		Salary ($)	~~Salary ($)~~		Bonus ($)	~~Bonus ($)~~		Option Awards ($)(1)	~~Option Awards ($)(1)~~		All Other Compensation ($)	~~All Other Compensation ($)~~		Total ($)	~~Total ($)~~
Bennett J. Yankowitz	2026	~~2025~~	$	$105,000	~~60,000~~	$	$—	-	$	$—	~~354,875~~	$	$—	-	$	$105,000	~~414,875~~
Chief Financial Officer	2025	~~2024~~	$	$60,000	~~36,000~~	$	$—	-	$	$354,875	-	$	$—	-	$	$414,875	~~36,000~~
Henrik Rouf	2026	~~2025~~	$	$300,000	~~120,000~~	$	$—	-	$	$—	~~709,750~~	$	$—	-	$	$300,000	~~829,750~~
Chief Executive Officer	2025	~~2024~~	$	$120,000	~~72,000~~	$	$—	-	$	$709,750	-	$	$—	-	$	$829,750	~~72,000~~

(1)

Calculated based on the grant-date fair value of the option awards granted during the fiscal year.

Employment Agreements and Change in Control Provision

On April 17, 2023, our Board of Directors approved an employment agreement for our chief executive officer, Henrik Rouf, and a consulting agreement for our chief financial officer, Bennett J. Yankowitz.

Mr. Rouf’s employment agreement provided for a base salary of $72,000 per year, commencing April 1, 2023, and has a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $120,000 and to extend the term to April 1, 2025. On July 1, 2025, the agreement was amended to increase Mr. Rouf’s annual salary to $360,000 and to extend the term to July 1, 2026.

Mr. Yankowitz’s consulting agreement provided for a base salary of $36,000 per year, commencing April 1, 2023, and has a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Yankowitz’s annual salary to $60,000 and to extend the term to April 1, 2025. On July 1, 2025, the agreement was amended to increase Mr. Yankowitz’s annual salary to $120,000 and to extend the term to July 1, 2026.

Outstanding Equity Awards at ~~2025~~2026 Fiscal Year-End

	Option Awards
	Number of securities underlying unexercised options (#)				Equity incentive plan awards: Number of securities underlying unexercised unearned options		Option exercise price		Option expiration
Name	Exercisable		Unexercisable		(#)		($)		Date
Henrik Keller		25,000		-		-	$	3.25	11/15/2034
Henrik Rouf		250,000		-		-	$	3.25	11/15/2034
Henrik Rouf (1)		-		250,000		-	$	3.25	11/15/2034
Peter Severin		50,000		-		-	$	3.25	11/15/2034
Bennett J. Yankowitz		125,000		-		-	$	3.25	11/15/2034
Bennett J. Yankowitz (1)		-		125,000		-	$	3.25	11/15/2034
Bennett J. Yankowitz (2)		25,000					$	10.00	12/31/2027
Andrew J. Ritter		50,000					$	1.90	8/7/2035
Torben S. Jensen		25,000					$	1.90	8/7/2035
Kim T. Mucke		25,000					$	1.90	8/7/2035

(1). Such options become vested on the closing date of the next acquisition by the Company of a company with a minimum independent valuation of $100 million.

21 (2). Consist of warrants that were granted outside of the 2024 Stock Incentive Plan.

Option Exercises and Stock Vested During Fiscal ~~2025~~2026

There were no options exercised during the fiscal year ended March 31, ~~2025~~2026.

Directors’ Compensation

On June 3, 2024, the Company’s Board of Directors adopted a resolution providing that the Chairman of the Board of Directors shall receive compensation of $20,000 per annum, and each other Director shall receive compensation of $10,000 per annum, in consideration of their serving on the Company’s Board of Directors, payable in equal installments semiannually in arrears, commencing December 31, 2024, without proration for partial terms.

Equity Compensation Plan Information

On June 7, 2024, our Board of Directors and stockholders adopted our 2024 Stock Incentive Plan (the “2024 Plan”). The 2024 Plan replaces the 2017 Non-Qualified Equity Incentive Plan that was adopted by the Board of Directors and stockholders on August 16, 2023 (the “2017 Plan”). The purpose of the 2024 Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship, and to stimulate an active interest of these persons in our development and financial success. Under the 2024 Plan, we are authorized to issue up to 7,000,000 shares of common stock, non-qualified stock options, performance shares, restricted stock and long-term incentive awards. The purpose of the 2024 Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship, and to stimulate an active interest of these persons in our development and financial success. Under the 2024 Plan, we are authorized to issue up to 7,000,000 shares of common stock, non-qualified stock options, performance shares, restricted stock and long-term incentive awards.

Administration. The 2024 Plan is administered by the Board of Directors or the committee or committees as may be appointed by the Board of Directors from time to time (the “Administrator”). The Administrator determines the persons who are to receive awards, the types of awards to be granted, the number of shares subject to each such award and the terms and conditions of such awards. The Administrator also has the authority to interpret the provisions of the 2024 Plan and of any awards granted there under and to modify awards granted under the 2024 Plan. The Administrator may not, however, reduce the price of options or stock appreciation rights issued under the 2024 Plan without prior approval of the Company’s shareholders.

Eligibility. The 2024 Plan provides that awards may be granted to employees, officers, directors and consultants of the Company or of any parent, subsidiary or other affiliate of the Company as the Administrator may determine. A person may be granted more than one award under the 2024 Plan.

Shares that are subject to issuance upon exercise of an option under the 2024 Plan but cease to be subject to such option for any reason (other than exercise of such option), and shares that are subject to an award granted under the 2024 Plan but are forfeited or repurchased by the Company at the original issue price, or that are subject to an award that terminates without shares being issued, will again be available for grant and issuance under the 2024 Plan.

Terms of Options and Stock Appreciation Rights. The Administrator determines many of the terms and conditions of each option and SAR granted under the 2024 Plan, including whether the option is to be an incentive stock option or a non-qualified stock option, whether the SAR is a related SAR or a freestanding SAR, the number of shares subject to each option or SAR, and the exercise price of the option and the periods during which the option or SAR may be exercised. Each option and SAR is evidenced by a grant agreement in such form as the Administrator approves and is subject to the following conditions (as described in further detail in the 2024 Plan):

(a) Vesting and Exercisability: Options, restricted shares and SARs become vested and exercisable, as applicable, within such periods, or upon such events, as determined by the Administrator in its discretion and as set forth in the related grant agreement. The term of each option is also set by the Administrator. However, a related SAR will be exercisable at the time or times, and only to the extent, that the option is exercisable and will not be transferable except to the extent that the option is transferable. A freestanding SAR will be exercisable as determined by the Administrator but in no event after 10 years from the date of grant.

(b) Exercise Price: Each grant agreement states the related option exercise price, which, in the case of SARs, may not be less than 100% of the fair market value of the Company’s shares of common stock on the date of the grant. The exercise price of an incentive stock option granted to a 10% stockholder may not be less than 110% of the fair market value of shares of the Company’s common stock on the date of grant.

(c) Method of Exercise: The option exercise price is typically payable in cash, common stock or a combination of cash of common stock, as determined by the Administrator, but may also be payable, at the discretion of the Administrator, in a number of other forms of consideration.

(d) Recapitalization; Change of Control: The number of shares subject to any award, and the number of shares issuable under the 2024 Plan, are subject to proportionate adjustment in the event of a stock dividend, spin-off, split-up, recapitalization, merger, consolidation, business combination or exchange of shares and the like. Except as otherwise provided in any written agreement between the participant and the Company in effect when a change in control occurs, in the event an acquiring company does not assume plan awards (i) all outstanding options and SARs shall become fully vested and exercisable; (ii) for performance-based awards, all performance goals or performance criteria shall be deemed achieved at target levels and all other terms and conditions met, with award payout prorated for the portion of the performance period completed as of the change in control and payment to occur within 45 days of the change in control; (iii) all restrictions and conditional applicable to any restricted stock award shall lapse; (iv) all restrictions and conditions applicable to any restricted stock units shall lapse and payment shall be made within 45 days of the change in control; and (v) all other awards shall be delivered or paid within 45 days of the change in control.

(e) Other Provisions: The option grant and exercise agreements authorized under the 2024 Plan, which may be different for each option, may contain such other provisions as the Administrator deems advisable, including without limitation, (i) restrictions upon the exercise of the option and (ii) a right of repurchase in favor of the Company to repurchase unvested shares held by an optionee upon termination of the optionee’s employment at the original purchase price.

Amendment and Termination of the 2024 Plan. The Administrator, to the extent permitted by law, and with respect to any shares at the time not subject to awards, may suspend or discontinue the 2024 Plan or amend the 2024 Plan in any respect; provided that the Administrator may not, without approval of the stockholders, amend the 2024 Plan in a manner that requires stockholder approval.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth the beneficial ownership of shares of our common stock, as of ~~July~~June 1518, ~~2025~~2026 of (i) each person known by us to beneficially own five percent (5%) or more of such shares; (ii) each of our directors and current executive officers named in the Summary Compensation Table; and (iii) our current executive officers and directors as a group. Except as otherwise indicated, all shares are beneficially owned, and the persons named as owners hold investment and voting power.

Beneficial ownership has been determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934. Under this rule, certain shares may be deemed to be beneficially owned by more than one person, if, for example, persons share the power to vote or the power to dispose of the shares. In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares, for example, upon exercise of an option or warrant, within 60 days of July 15, 2025. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person, and only such person, by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table does not necessarily reflect the person’s actual voting power at any particular date.

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership			Percentage of Class (1)
Henrik Rouf (CEO) 7950 W. Sunset Blvd – Suite 629 Los Angeles, CA 90046 USA		292,640	(2)		1.7	%
Bennett Yankowitz (CFO & Director) 280 S. Beverly Dr., Suite 505 Beverly Hills, CA 90212		150,000	(3)		0.9	%
Henrik Keller (Director) Bernstoffslund Alle 59 2920 Charlottenlund Denmark		25,000			0.1	%
Peter Severin (Director/Chairman) Blaamunkevangen 1 3120 Dronningmoelle Denmark		50,000			0.3	%
All officers and directors as a group (4 persons)		517,640			3.0	%
Kiri Lillan Glaesner Dyrehavevej 3B 2930 Klampenborg Denmark		3,275,325	(4)		18.7	%
Allan Traugott Wehnert Dyrehavevej 3B 2930 Klampenborg Denmark		5,296,131	(5)		30.2	%
Torben Steen Jensen Dyrehavevej 3B 2930 Klampenborg Denmark		3,017,353	(6)		17.2	%
Christian Hill-Madsen Mesterlodden 3A, 1. 2820 Gentofte Denmark		1,156,446	(7)		6.6	%

	(1)	Based on 17,562,138 shares of common stock as of July 15, 2025, composed of 17,487,138 outstanding shares of our common stock and 75,000 shares of our common stock underlying outstanding warrants.
	(2)	Includes 42,000 shares of our common stock owned by Reddington Partners LLC, of which Mr. Rouf is the sole beneficial owner.
	(3)	On November 28, 2022, Mr. Yankowitz was granted a warrant to purchase 25,000 shares of our common stock at $10.00 per share.
	(4)	Held through GK Partners ApS, which is controlled by Mrs. Glaesner.
	(5)	Held through Alteral Therapeutics ApS, which Mr. Wehnert controls. Mr. Wehnert is the CEO of the Company’s subsidiaries Orocidin A/S and Bio-Convert A/S.
	(6)	Held through AC Nordic ApS, which is controlled by Mr. Jensen.
	(7)	Held through ABCHill Holding ApS, which is controlled by Mr. Hill-Madsen. Mr. Hill-Madsen was formerly a director of the Company and is the CEO of the Company’s subsidiary, NP Bioinnovation A/S.

Beneficial ownership has been determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934. Under this rule, certain shares may be deemed to be beneficially owned by more than one person, if, for example, persons share the power to vote or the power to dispose of the shares. In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares, for example, upon exercise of an option or warrant, within 60 days of June 18, 2026. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person, and only such person, by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table does not necessarily reflect the person’s actual voting power at any particular date.

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership			Percentage of Class (1)
Henrik Rouf (CEO) 280 S. Beverly Dr., Suite 505 Beverly Hills, CA 90212 USA		265,973	(2)		1.4	%

Bennett Yankowitz (CFO & Director) 280 S. Beverly Dr., Suite 505 Beverly Hills, CA 90212 USA		150,000	(3)		0.8	%

Henrik Keller (Former Director) Bernstoffslund Alle 59 2920 Charlottenlund Denmark		25,000			0.1	%

Peter Severin (Director/Chairman) Blaamunkevangen 1 3120 Dronningmoelle Denmark		50,000			0.3	%

Andrew J. Ritter (Director) 11811 San Vicente Blvd. Los Angeles, CA 90049 USA		50,000			0.3	%

Kim T. Mucke (Director) Oesterbrogade 110, 3_ 2100 Copenhagen Oe Denmark		97,399	(4)		0.1	%

Torben Steen Jensen (Director) Strandvejen 60, 5 2900 Hellerup Denmark		3,144,335	(5)		16.3	%

All officers and directors as a group (7 persons)		3,710,308			19.3	%

Kiri Lillan Glaesner Dyrehavevej 3B 2930 Klampenborg Denmark		3,259,025	(6)		17.0	%

Allan Traugott Wehnert Dyrehavevej 3B 2930 Klampenborg Denmark		5,296,131	(7)		27.6	%

Christian Hill-Madsen Mesterlodden 3A, 1. 2820 Gentofte Denmark		1,098,973	(8)		5.7	%

	(1)	Based on 19,798,896 shares of common stock as of June 18, 2026, composed of 19,173,896 outstanding shares of our common stock, 550,000 shares of our common stock underlying outstanding incentive stock options and 75,000 shares of our common stock underlying outstanding warrants.
	(2)	Includes 15,333 shares of our common stock owned by Reddington Partners LLC, of which Mr. Rouf is the sole beneficial owner and 250,000 shares of our common stock underlying outstanding incentive stock options.
	(3)	On November 28, 2022, Mr. Yankowitz was granted a warrant to purchase 25,000 shares of our common stock at $10.00 per share. Also includes 125,000 shares of our common stock underlying outstanding incentive stock options.
	(4)	Consists of 72,399 shares owned by KTM ApS, a company 100% owned by Mr. Mücke, and 25,000 shares of our common stock underlying outstanding incentive stock options.
	(5)	Held through AC Nordic ApS, which is controlled by Mr. Jensen. Includes incentive stock options to purchase 25,000 shares.
	(6)	Held through GK Partners ApS, which is controlled by Mrs. Glaesner.
	(7)	Held through Alteral Therapeutics ApS, which Mr. Wehnert controls. Mr. Wehnert is the CEO of the Company’s subsidiaries Orocidin A/S, Bio-Convert A/S and NoviThera ApS.
	(8)	Held through ABCHill Holding ApS, which is controlled by Mr. Hill-Madsen. Mr. Hill-Madsen was formerly a director of the Company and is the CEO of the Company’s subsidiary, NP Bioinnovation A/S.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Mr. Tom ~~Glasner~~Glaesner Larsen is the spouse of Mrs. Glaesner, CEO of GK Partners and was a member of our board of directors from February 23, 2023 until his voluntary retirement on June 9, 2023. He was a beneficial owner of a controlling interest in NP Bioinnovation A/S (formerly Managementselskabet af 12.08.2020 A/S) until its acquisition by the Company on February 23, 2023. He was also a beneficial owner of a controlling interest in Orocidin A/S until its acquisition by the Company on May 13, 2024, and a beneficial owner of a controlling interest in Bio-Convert A/S until its acquisition by the Company on November 11, 2024.

Effective April 1, 2022, we issued to GK Partners, for financial services, a warrant (the “2022 GK Warrant”) to purchase up to 600,000 shares of our ~~Common~~common ~~Stock~~stock at an exercise price of $10.00 per share, and which had an expiration date of December 31, 2023. The Company determined that the 2022 GK Warrant is not precluded from equity classification and was therefore recorded within additional paid-in capital on the Company’s consolidated balance sheets at its issuance date fair value. On December 22, 2023, the expiration date of the warrant, covering 570,500 remaining unexercised warrant shares, was extended to December 31, 2024 . During the year ended March 31, 2024, GK Partners exercised a portion of its warrant for a total of 30,600 shares. The exercise price was $10.00 per share for total proceeds of $306,000. For the year ended March 31, 2025, GK Partners exercised a portion of its warrant for 57,400 shares. The exercise price was $10.00 per share for total proceeds of $576,000. On December 31, 2024 the 2022 GK Warrant expired.

Effective December 30, 2024, a new warrant was issued to GK Partners (the “2024 GK Warrant”) to purchase up to 1,000,000 shares of the Company’s ~~Common~~common ~~Stock~~stock at an exercise price equal to the greater of $8.91 and the daily volume weighted average price of the ~~Common~~common ~~Stock~~stock for the ten trading days immediately preceding the date of exercise. The 2024 GK Warrant ~~expires~~expired on December 31, 2025. The Company determined that the 2024 GK Warrant was precluded from being classified within equity and was liability classified under ASC Topic 815, Derivatives and Hedging. During the year ended March 31, 2025, GK Partners exercised a portion of its 2024 GK Warrant ~~for~~ for a total of 35,176 shares. The exercise price ranged from $8.91 to $8.95 per share for total proceeds of $313,455. As of March 31, 2025, the 2024 GK Warrant was terminated. Therefore, as of March 31, 2025, the Company recognized no warrant liability on the consolidated balance sheet. The measurement of fair value of the 2024 GK Warrants was determined utilizing a Monte Carlo ~~Simulation~~simulation model considering all relevant assumptions current as of March 31, 2025 presented in Note 69. The change in fair value resulting from the issuance of ~~2024~~the 2024 GK Warrant was recognized in change in fair value of warrant liability (related party) in the amount of $172,715 on the consolidated statement of operations and comprehensive loss for the year ended March 31, 2025. On March 31, 2025, the 2024 GK Warrants were terminated, and the remaining shares were recorded toat a fair value of $167,000 to additional paid -in capital at due to the related party relationship.

As detailed in Note 4 to the Consolidated Financial Statements included in this Report, on June 20, 2023, the Company and GK Partners entered into a Stock Purchase and Sale Agreement whereby the Company acquired equity interests in Mag Mile.

Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $79,463 and $17,022 for the years ended March 2025 and 2024, respectively. As of March 31, 2025 and March 31, 2024, we had no outstanding payable due to the Affiliate for either period.26

Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $79,488 and $79,463 for the years ended March 31, 2026 and 2025, respectively. As of March 31, 2026 and March 31, 2025, we had no outstanding payable due to the Affiliate for either period.

Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $120,000 and to extend the term to April 1, 2025.On July 1, 2025 the agreement was amended to increase Mr. Rouf’s annual salary to $360,000 and to extend the term to July 1, 2026.

During the year ended March 31, 2025, a related party forgave their payable of $13,886. The amount has been credited to additional paid in capital.

Item 14. Principal Accountant Fees and Services

The following is a summary of the fees billed to us by our independent registered public accounting firm, for professional services rendered during the fiscal ~~year~~years ended March 31, ~~2025~~2026 and ~~2024~~2025.

	2025		2024
	March 31, 2026		March 31, 2025
Audit fees – Fruci & Associates II, PLLC	$	55,035	$	26,500
Audit fees - Fruci & Associates II, PLLC	$	72,406	$	55,035
Audit related fees	$	—3,098	$	~~3,300~~—
Tax fees	$	—	$	—
All other fees	$	—	$	—
Total	$	5575,~~035~~504	$	2955,~~800~~035

All of the professional services rendered by principal accountants for the audit of our annual financial statements that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the last two fiscal years were approved by our board of directors.

Audit Fees

~~Consist~~Audit fees consist of fees billed for professional services rendered for the audit of our financial statements, ~~and~~the review of interim financial ~~statements~~ statements included in quarterly reports and services that are normally provided by the principal accountants in connection with statutory and regulatory filings or engagements.

Audit Related Fees

~~Consist~~Audit-related fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees”.

Tax Fees

~~Consist~~Tax fees consist of fees billed for professional services for tax compliance, tax advice and tax planning. These services include preparation of federal and state income tax returns.

All Other Fees

~~Consist~~All other fees consist of fees for ~~product~~products and services other than the services reported above.

26Item 15. Exhibits and Financial Statement Schedules

PART IV

Item 15. Exhibits

The following exhibits are filed as part of this Annual Report.

Exhibit				Filed or Furnished
Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
3.1	Certificate of Incorporation and Amendments	S-1	3.1	12/06/2023
3.2	Certificate of Amendment to Certificate of Incorporation, as filed with the Delaware Secretary of State, dated May 13, 2023	8-K		5/22/23
3.3	Bylaws	S-1	3.2	12/06/2023
10.1	Stock Purchase Agreement dated as of October 12, 2021 between EKIMAS Corporation and Reddington Partners LLC.	8-K	10.1	10/18/21
10.2	Indemnification Agreement dated as of October 12, 2021 between EKIMAS Corporation and Bennett J. Yankowitz.	8-K	10.2	10/18/21
10.3	Warrant dated as of April 1, 2022 issued by EKIMAS Corporation to GK Partners ~~AsP~~ApS.	8-K	10.1	4/12/2022
10.4	Demand Promissory Note, dated October 14, 2022, made by the Company to the Lender.	8-K	10.1	10/17/2022
10.5	Warrant to Purchase Common Stock, dated November 28, 2022, issued to David Volpe	8-K	10.1	11/30/2022
10.6	Warrant to Purchase Common Stock, dated November 28, 2022, issued to Bennett J. Yankowitz	8-K	10.2	11/30/2022
10.7	Contribution Agreement dated February 23, 2023 among Nordicus Partners Corporation, Nordicus Partners A/S, GK Partners ApS, Henrik Rouf and Life Science Power House ApS	S-1	10.11	12/06/2023
10.8	Stock Purchase and Sale Agreement, dated as of June 20, 2023, between Nordicus Partners Corporation and GK Partners ApS	8-K	10.1	6/20/2023
10.9	2017 Non-Qualified Equity Incentive Plan	~~8_K~~8-K	10.37	8/22/2017
10.10	Second Amended and Restated Employment Agreement, dated as of April 1, 2024, between EKIMAS Corporation and Henrik Rouf	10-K	10.10	7/13/2024
10.11	Second Amended and Restated Consulting Agreement, dated as of April 1, 2024, between EKIMAS Corporation and Bennett J. Yankowitz	10-K	10.11	7/13/2024
10.12	Stock Purchase and Sale Agreement, dated as of May 13, 2024, between the shareholders of Orocidin A/S and the Company	8-K		5/16/2024
10.13	Third Amended and Restated Employment Agreement, dated as of July 1, 2025, between the Company and Henrik Rouf	8-K	10.1	7/1/2025
10.14	Third Amended and Restated Consulting Agreement, dated as of July 1, 2025, between the Company and Bennett J. Yankowitz	8-K	10.2	7/1/2025
10.15	Warrant dated as of December 30, 2024 issued by Nordicus Partners Corporation to GK Partners ApS.	8-K	10.1	1/1/2025
10.16	2024 Stock Incentive Plan	14C	Annex A	5/28/2024
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
31.2	Certification of the Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
101.INS	Inline XBRL Instance Document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema Document.				X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.				X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.				X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.				X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.				X
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				X

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 29, 2025	Nordicus Partners Corporation
	By	/s/ Henrik Rouf
		Henrik Rouf
		Chief Executive Officer and Principal Executive
	By	/s/ Bennett J. Yankowitz
		Bennett J. Yankowitz
		Director, Chief Financial Officer Principal Financial and Accounting Officer
	By	/s/ Peter Severin
		Peter Severin
		Chairman
	By	/s/ Henrik Keller
		Henrik Keller
		Director

10.1	Second Amended and Restated Employment Agreement, dated as of April 1, 2024, between EKIMAS Corporation and Henrik Rouf	10-K	10.1	7/13/2024
10.11	Second Amended and Restated Consulting Agreement, dated as of April 1, 2024, between EKIMAS Corporation and Bennett J. Yankowitz	10-K	10.11	7/13/2024
10.12	Stock Purchase and Sale Agreement, dated as of May 13, 2024, between the shareholders of Orocidin A/S and the Company	8-K		5/16/2024
10.13	Third Amended and Restated Employment Agreement, dated as of July 1, 2025, between the Company and Henrik Rouf	8-K	10.1	7/1/2025
10.14	Third Amended and Restated Consulting Agreement, dated as of July 1, 2025, between the Company and Bennett J. Yankowitz	8-K	10.2	7/1/2025
10.15	Warrant dated as of December 30, 2024 issued by Nordicus Partners Corporation to GK Partners ApS.	8-K	10.1	1/1/2025
10.16	2024 Stock Incentive Plan	14C	Annex A	5/28/2024
10.17	Directors Agreement, dated as of August 7, 2025, between the Company and Torben Jensen.	8-K	10.1	8/7/2025
10.18	Directors Agreement, dated as of August 7, 2025, between the Company and Kim T. Mücke.	8-K	10.2	8/7/2025
10.19	Directors Agreement, dated as of August 7, 2025, between the Company and Andrew J. Ritter.	8-K	10.3	8/7/2025
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
31.2	Certification of the Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
99.1	Audit Committee Charter of Nordicus Partners Corporation				X
99.2	Compensation Committee Charter of Nordicus Partners Corporation				X
99.3	Nominating Committee Charter of Nordicus Partners Corporation				X
101.INS	Inline XBRL Instance Document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema Document.				X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.				X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.				X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.				X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.				X
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				X

Item 16. Form 10-K Summary

None.

SIGNATURES

Dated: July 14, 2026

Nordicus Partners Corporation

	By	/s/ Henrik Rouf
		Henrik Rouf
		Chief Executive Officer and Principal Executive Officer

	By	/s/ Bennett J. Yankowitz
		Bennett J. Yankowitz
		Director, Chief Financial Officer Principal Financial and Accounting Officer

Filing Compare · Nordicus Partners Corp